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Proteasome-dependent protein degradation plays an important role in 
regulating many cellular processes. Central to protein degradation is the 
tagging of substrates with ubiquitin polypeptides. The addition of ubiquitin 
polypeptides to substrate proteins, termed ubiquitination, is the prerequisite for 
substrate recognition by the 26S proteasome. Ubiquitination is mediated by E3 
ubiquitin ligases, among which Cullin E3 ligases form the largest family. The 
aim of this study is to achieve a better understanding of the function and 
regulation of Cullin E3 ligases. 
 
We first studied the degradation of insulin receptor substrate 1 (IRS1) by the 
Cullin5 E3 ubiquitin ligase. IRS1 is an important signaling intermediate in the 
insulin signaling pathway. Previously it was reported that IRS1 activity and 
protein stability is regulated by suppressor of cytokine (SOCS) proteins. 
SOCS proteins are known to bind to Cullin5 and function as substrate 
receptors that recruit substrates for ubiquitination. Therefore, we investigated 
whether Cullin5 is involved in mediating IRS1 protein degradation. We found 
that the basal degradation of the IRS1 protein is not dependent on Cullin5. 
Signal-induced IRS1 degradation by the mTORC1/S6K and PKCα pathway 
was similarly found not to be mediated by Cullin5. Therefore, our results 
suggest that SOCS proteins do not mediate IRS1 degradation by functioning 





Next, we investigated the regulation of the Cullin1 E3 ligase substrate receptor 
module, which consists of the adapter protein Skp1 and one of approximately 
70 different substrate recognition subunits (F-box proteins). Of note, the 
inhibition of substrate degradation through inhibition of SCF is currently being 
explored as a potential chemotherapy strategy against cancer, highlighting the 
importance of understanding the mechanism of SCF complex assembly. 
Currently there is limited information on whether F-box proteins always exist 
in a complex with Skp1 in vivo. Using Skp2 as model F-box protein, we found 
that Skp1 protein exists in moderate excess over Skp2 and does not 
significantly regulate the steady state level of Skp2 protein. Skp2 exists largely 
in a non-Skp1 bound form. Given that Skp2 has the greatest binding affinity 
for Cullin1 among the 69 F-box proteins, it is likely that other F-box proteins 
also exist to a large proportion in a non-Skp1 bound form. We propose a 
model whereby the F-box protein dynamically associates with Skp1. Targeting 
the dynamic interaction of F-box proteins and Skp1 may be a promising 
therapeutic strategy against cancer. 
 
Lastly, we have characterized for the first time Skp1a, a splice variant of the 
commonly-studied Skp1b protein. The expression of Skp1a is low in the panel 
of cell lines examined. This is due to preferential splicing of Skp1b. In 
addition, Skp1a is a highly unstable protein, likely due to being more unfolded 
and susceptible to aggregation or proteolytic cleavage in cells. There is also a 
difference between Skp1a and Skp1b cellular distribution, with Skp1b 
showing a greater nuclear localization compared to Skp1a. We observed 
stronger binding of Skp1b to both Skp2 F-box protein and the kinetochore 
vi 
 
assembly factor SGT1, suggesting functional differences between Skp1a and 
Skp1b. The results of this study suggest that Skp1a may have alternate 
functions from Skp1b. Taken together, the study provides new insights into 
the function and regulation of Cullin E3 ligases and opened up new direction 
for further research. 
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Maintenance of cellular protein levels is a tightly regulated process. 
Deregulation of protein levels in the cell can lead to chronic diseases including 
cancer and neurodegenerative disease. An example is Alzheimer’s disease, 
where the molecular pathogenesis is characterized by normal amyloid β-
protein production but abnormal clearance by the proteasome (Lopez Salon et 
al. 2003; Mawuenyega et al. 2010; Saido & Leissring 2012). Apart from 
maintaining proper turnover of proteins in the cell, protein degradation also 
functions as a regulatory switch in cell signaling pathways. The p53 tumor 
suppressor is one of the most well-studied proteins in the oncology field. The 
p53 protein is unstable as result of constitutive degradation via the 26S 
proteasome. In response to various stress signals, for instance DNA damage, 
p53 is stabilized and functions to induce cell cycle arrest and apoptosis. 
Failure to “switch on” the p53 pathway through inhibition of p53 
ubiquitination and proteasome-dependent degradation leads to tumor 
formation and progression (Jain & Barton 2010; Devine & Dai 2013). Thus, 
the selectivity and regulation of the protein degradation pathway is critical in 
maintaining cellular integrity.  
 
1.1 Components of the ubiquitin proteasome system (UPS) 
An ATP-dependent pathway of protein degradation was initially discovered in 
1977 by Etlinger and Goldberg (Etlinger & Goldberg 1977). It was 
subsequently determined by Rechsteiner and co-workers that this pathway is 
mediated through the 26S proteasome (Hough, Pratt & Rechsteiner 1986). The 
26S proteasome complex is highly conserved from yeast to mammalian cells, 
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indicating its importance in cellular function. Being found in both the nucleus 
and cytoplasm compartment of the cell, the proteasome is responsible for the 
degradation of 80% of the cellular proteins. It is a multi-subunit protein 
assembly which is comprised of a barrel-shaped proteolytic core complex (20S 
proteasome) and capped with 19S regulatory complexes acting as a lid 
(reviewed in Voges, Zwickl & Baumeister 1999). The core complex is made 
up of different α and β-type subunits, with the β2, β5 and β1 subunits 
exhibiting trypsin-like, chymotrypsin-like and post-glutamyl peptide 
hydrolytic activities respectively. Various proteasome inhibitors that target 
these catalytic β-subunits have been developed. 
 
Proteins are targeted for degradation via the attachment of a poly-ubiquitin 
chain followed by recognition by the 19S complex, which specifically 
recognizes and binds to substrates that are tagged with poly-ubiquitin chains 
(Voges, Zwickl & Baumeister 1999). Ubiquitin is a 76 amino acid peptide and 
derives its name from being “represented universally in living cells” 
(Goldstein et al. 1975). The C-terminal glycine residue of the first ubiquitin 
peptide is attached to a lysine side chain of the substrates via an isopeptide 
bond. Subsequently, multiple ubiquitin peptides are covalently attached in a 
chain via a process called polyubiquitination. As ubiquitin peptide contains 
seven lysine residues (K6, K11, K27, K29, K33, K48, and K63), distinct poly-
ubiquitin chains can be formed. Often, K-48 polyubiquitination chains mediate 
the proteasomal degradation of substrates (Chau et al. 1989; Jacobson et al. 
2009). To be recognized by the 19S complex, substrate require chains of four 
or more K-48 covalently linked ubiquitin polypeptides (Clague & Urbé 2010). 
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On the other hand, K63-linkages regulate several processes such as ribosomal 
function (Spence et al. 2000), DNA replication and repair (Ulrich & Walden 
2010), intracellular trafficking (Acconcia, Sigismund & Polo 2009), and 
modulate the NF-ĸB signaling pathway (Skaug, Jiang & Chen 2009). 
  
1.2 The ubiquitination cascade 
The proteins or protein complexes that mediate the conjugation of ubiquitin 
peptides onto the substrate protein are called E3 ligases. Covalent linkage of 
ubiquitin onto the substrates involves E1 ubiquitin-activating enzyme, E2 
ubiquitin-conjugating enzyme and E3 ubiquitin ligase. This three step cascade 
was discovered by Avram Hershoko and colleagues in the early 1980s 
(Hershko et al. 1983; Hershko, Ciechanover & Varshavsky 2000). The 
ubiquitination cascade is initiated when an E1 enzyme activates ubiquitin in an 
ATP-dependent manner, forming an adenylate conjugate and subsequently a 
thioester bond with the E1 enzyme. The ubiquitin is then passed to the active 
site cysteine of the E2 enzyme, forming a thioester bond with the C-terminal 
glycine on the ubiquitin. The ubiquitin from E2 enzyme is subsequently 
transferred to the substrate protein in a process guided by the E3 ligase. 
Specifically, the function of the E3 ligase is to bring the substrate and the 
ubiquitin-charged E2 enzyme into close proximity for the formation of an 
isopeptide bond between the lysine residue of the substrate and C-terminal 
glycine on the ubiquitin (Scheffner, Nuber & Huibregtse 1995). In addition to 
the identification of the three step ubiquitination cascade, Avram Hershoko 
and colleagues also discovered that the substrate selectivity of the 
ubiquitination process is dependent on the E3 ligase (Hershko et al. 1986). 
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Thus, ubiquitin ligases were found to contain specific substrate binding 
domains that confer specificity. 
 
1.3 E3 ubiquitin ligases 
There are two main classes of E3 ubiquitin ligases - HECT (Homologous to 
the E6-AP Carboxyl Terminus) and RING E3 ligase. Together, these E3 
ligases mediate the ubiquitination and degradation of most proteasome 
substrates in the cell.  
 
The HECT family of ligases can be further subdivided into the Nedd4 family, 
the HERC (HECT and RCC1 (regulator of chromosome condensation 1)) 
family and other families. The conserved cysteine amino acid found in the 
HECT domain forms a transient thioester bond with the carboxyl group of the 
C-terminal glycine on the ubiquitin and then transfers the ubiquitin onto a 
lysine residue on the substrate, forming an isopeptide bond. The transient 
covalent bond between ubiquitin and the E3 ligase is a specific feature of 
HECT E3 ligases. This family of E3 ligases is known to regulate cell signaling, 
protein trafficking, viral budding, cancer progression and immune responses 
(Rotin & Kumar 2009). 
 
The family of RING E3 ligases contains a myriad of sub-families that is 
characterized by the inclusion of a RING (Really Interesting New Gene)-
finger domain or subunit that is required for the ligase function. This family of 
proteins includes the Anaphase Promoting Complex/Cyclosome (APC/C), the 
Cullin RING E3 ubiquitin ligase family as well as numerous other E3 ligase 
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enzymes (such as Mdm2 and Parkin). The APC/C family of ligases 
predominantly regulates cell cycle progression by mediating timely 
degradation of substrates. APC/C is composed of 13 subunits and the RING 
domain protein apc11. The APC/C E3 ligase recognizes substrates through the 
substrate adaptor proteins Cdc20 and Cdh1 (Zhang et al. 2014). Similar to the 
APC/C E3 ligase, members of the Cullin RING E3 ubiquitin ligase (CRL) 
family are multi-subunit complexes. CRLs bind to the RING domain proteins 
Rbx1 or Rbx2 (Ohta et al. 1999). By mediating the degradation of numerous 
cellular substrates, this family of E3 ligases exerts control over critical cellular 
processes such as cell cycle progression, DNA damage response and apoptosis 
(Sarikas, Hartmann & Pan 2011). 
 
1.4 Cullin RING E3 ubiquitin ligase (CRLs) 
CRLs were discovered in 1996 by two independent research groups for their 
role in the cell cycle exit in C. elegans and G1/S phase transition in yeast 
(Mathias et al. 1996; Kipreos et al. 1996). Cullins are named after their 
function of ‘culling’ substrates, by directing proteins for proteasomal 
degradation after facilitating the addition of ubiquitin onto the substrate 
(Kipreos et al. 1996; Guardavaccaro & Pagano 2004). This family is 
evolutionarily conserved from yeast to humans, and is the largest family of E3 
ligases accounting for the degradation of about 20% of proteins degraded by 
the UPS (Soucy et al. 2009). 
 
There are seven mammalian homologues of Cullins (Cul1, Cul2, Cul3, Cul4a, 
Cul4b, Cul5 and Cul7). The Cullin RING E3 ligases (CRLs) exist as a 
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complex of different subunits, with Cullin acting as a scaffold protein for the 
E3 ligase complex. The adaptor protein and substrate receptor subunits form 
the substrate receptor module and bind to the Cullin N-terminus. This 
substrate receptor module is responsible for recruiting E3 ligase substrates. A 
RING-domain containing protein binds to the C-terminus of the Cullin and 
recruits the E2 ubiquitin-conjugating enzyme, which is responsible for the 
transfer of ubiquitin onto the substrate. Polyubiquitination, the repeated 
addition of ubiquitin to the substrate, subsequently leads to recognition and 
degradation of the substrate by the 26S proteasome. 
 
There are two RING proteins that can bind to the CRLs, Rbx1 and Rbx2. Both 
Rbx1 (alternative names include Roc1 or Hrt1) and Rbx2 (also known as Roc2 
or SAG) contain the RING-H2 finger domain, but differ in binding partners 
and expression. Rbx1 binds to Cullin2 whereas Rbx2 preferentially binds to 
Cullin5 (Kamura et al. 2004). In addition to Cullin2, Rbx1 also binds to 
Cullin1, Cullin3, Cullin4a, Cullin4b and Cullin7. Although the expression of 
both RING proteins can be induced upon mitogenic stimulation (Ohta, Michel 
& Xiong 1999), it has been shown that Rbx1 is constitutively expressed 
whereas Rbx2 is stressed inducible (Sun et al. 2001). Rbx2 expression is 
induced under a variety of conditions such as hypoxia (Tan et al. 2008), 
ischemia/ reoxygenation (Yang et al. 2001; Chanalaris et al. 2003), redox 
agents (Duan et al. 1999), nitric oxide (Yang & Park 2006), UV (He et al. 
2008), TPA (Gu, Tan & Sun 2007), heat shock (Lee et al. 2008), and MMP+ 




Prior to substrate ubiquitination mediated by CRLs, a crucial activation step is 
necessary to confer activity to the E3 ligase. Neddylation is the process of 
adding a single Nedd8 polypeptide to a conserved lysine residue at the Cullin 
C-terminus. This process is similar to ubiquitination whereby a Nedd8-specific 
E1 activating enzyme and E2 conjugating enzyme is required for the 
conjugation of a Nedd8 polypeptide to CRLs. The attachment of Nedd8 causes 
a conformational change in the Cullin complex and this facilitates ubiquitin 
transfer by bringing the ubiquitin-charged E2 ubiquitin conjugating enzyme 
into a closer proximity with the substrate (Yamoah et al. 2008; Saha & 
Deshaies 2008; Duda et al. 2008). Upon dissociation of ubiquitinated substrate, 
the COP9 signalosome will remove Nedd8, leading to the inactivation of 
CRLs. 
 
To define the physiological role of CRLs, several genetic mouse knockout 
models were created. As shown in table 1.1, complete removal of CRL core 
subunits confers early embryonic lethality. This is due to the accumulation of 
substrates normally degraded by CRLs, disrupting many essential signaling 
pathways involved in embryogenesis and cellular development. In contrast, 
only the knockout of certain substrate receptors causes embryonic lethality 





Table 1.1 Knockout mouse models of the various CRL components and the corresponding phenotypes. There are no reported Cullin2, 
Cullin5 and Nedd8 knockout mouse models as of April 2015. 
  
 
CRL component Gene disrupted 
Protein encoded  
by gene 
Viability of KO mice (Embryonic day) Reference 
Cullin 
scaffold 
CUL1 Cullin1 Embryonic lethal (E5.5) 
(Wang et al. 1999) 
(Dealy et al. 1999) 
CUL2 Cullin2 Embryonic lethal (before E7.5) (Singer et al. 1999) 
CUL4a Cullin4a Embryonic lethal (E4.5 to E7.5) (Li, Ruiz & Chun 2002) 
CUL4b Cullin4b 
Embryonic lethal (before E9.5) 
Embryonic lethal (before E7.5) 
(Liu et al. 2012) 
(Jiang et al. 2012) 
CUL7 Cullin7 Neonatal lethal (Skaar, Arai & DeCaprio 2005) 
RING-finger 
protein 
RNF7 Rbx1 Embryonic lethal (before 7.5) (Tan et al. 2009) 
RBX2 Rbx2 Embryonic lethal (E11.5 to12.5) (Tan et al. 2011) 
Nedd8 
COPS2  CSN2 Early embryonic lethality (Lykke-Andersen et al. 2003) 
UBA3 UBE1C Embryonic lethal (before E7.5) (Tateishi et al. 2001) 
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1.41 Skp1-Cullin1-F-box (SCF) 
The SCF (Skp1-Cullin1-F-box) E3 ligase is the most well-characterized 
complex and forms one of the largest classes of CRLs with at least 69 different 
substrate receptors (Skowyra et al. 1997; Feldman et al. 1997). F-box proteins 
function as substrate receptors of SCF E3 ligases and confer specificity in 
recognizing appropriate substrates for degradation (Figure 1A). The three best-
characterized F-box proteins are Fbxw7, β-TrCP and Skp2. These F-box 
proteins are known to contribute to the oncogenesis process by regulating the 
stability of key substrates such as c-myc, β-catenin and p27 (Guardavaccaro & 
Pagano 2004). Their function is also deregulated in cancer as a consequence of 
mutations or altered expression. As such, CRLs and specifically SCF ligases 
are of great importance in cancer research. 
 
 
Figure 1A. Structure of Cullin RING E3 ubiquitin ligases 
The Cullin protein acts as scaffold protein for the CRL complex. A RING-
domain containing protein is bound to the C-terminus of the Cullin and 
recruits the ubiquitin-charged E2 conjugating enzyme. The substrate receptor 
module, which consists of the adaptor protein and the substrate receptor, 
recruits specific substrates to the CRL. The C-terminus of Cullin is modified 




Mouse knockout models have also been established for Fbxw7, β-TrCP and 
Skp2 substrate receptor proteins. Surprisingly, only the knockout of Fbxw7 
causes embryonic lethality, with viable and fertile β-TrCP-/- and Skp2-/- mice 
(Tsunematsu et al. 2004; Tetzlaff et al. 2004; Nakayama et al. 2000; 
Guardavaccaro et al. 2003; Nakayama et al. 2003). These results suggest that 
embryogenesis and cellular development are regulated through overlapping 
signaling pathways governed by the different substrate receptors of the CRL 
degradation pathway. 
 
1.5 Implication of CRLs in diseases  
Given the phenotype of the CRL and substrate receptor knockout models, it is 
not surprising that the deregulation of CRL subunits results in the disruption of 
various signaling pathways required for cellular integrity. Any alterations in 
crucial pathways can lead to disease development and progression. The role of 
CRLs in tumorigenesis is an important area of research and is widely studied. 
There are many human association studies between the type of cancer and the 
aberrant CRL component (reviewed in Nakayama & Nakayama 2006). In 
addition, CRLs have been proposed to be good diagnostic and/or prognostic 
markers for cancer (reviewed in Sun 2006).  
 
One prominent CRL subunit with alterations found in many human cancers is 
the Skp2 substrate receptor (reviewed in Wang et al. 2012; Nakayama & 
Nakayama 2006). In addition, various mouse models showed that Skp2 protein 
has a causal role as a tissue-specific oncogene or onco-cooperative gene, 
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notably through the degradation of tumor suppressor proteins such as p21, p27 
and Foxo1 (reviewed in Zhou, Wei & Sun 2013). 
 
1.6 Chemotherapeutic drugs targeting the UPS 
As early as the late 1900s, researchers have identified the importance of the 
protein degradation system as a therapeutic target in cancer therapy (Hershko, 
Ciechanover & Varshavsky 2000). Although both normal and cancerous cells 
require the proteasome for their physiological function, cancer cells have been 
shown to require a higher level of proteasome activity (An et al. 1998; Chen & 
Madura 2005; Zhang et al. 2004). As such, inhibition of the proteasome 
should selectively eliminate cancer cells. 
 
The potential of using a proteasome inhibitor to target cancer cells was 
exemplified by the discovery of bortezomib (codenamed PS-341). This drug 
was developed in 1995 under the US trade name Velcade and by May 2003, 
the FDA (United States Food and Drug Administration) has granted the 
approval for its use in relapsed/ refractory myeloma 
(http://www.myelomabeacon.com/resources/2008/10/15/velcade/ 2 September 
2011 viewed 18 July 2014). Currently, bortezomib is used for the treatment of 
both multiple myeloma and mantle cell lymphoma. Being the first of its kind 
in cancer therapy classification, bortezomib targets the downstream protein 
degradation pathway as its mechanism of action (Sánchez-Serrano 2006). 
Bortezomib is a dipeptide boronic acid that specifically and reversibly inhibits 
the chymotrypsin activity of the 26S proteasome. There are several 
downstream pathways that have been suggested to contribute to the selective 
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killing of cancer cells and consequently to tumor regression. One such 
pathway is through inducing Bcl-2 phosphorylation and its subsequent 
cleavage, leading to apoptosis as demonstrated by DNA fragmentation and 
PARP cleavage (Ling et al. 2002). Bortezomib also acts via preventing NF-ĸB 
activation, a pathway essential for cancer cell survival. This results in greater 
tumor sensitivity to chemotherapeutic and radioactive agents (Palombella et al. 
1994; Adams 2004; Adams 2002). Furthermore, the drug causes endoplasmic 
reticulum (ER) stress. Excessive ER stress leads to apoptosis in myeloma cells, 
which have a greater requirement for ER-mediated protein folding. Though 
targeting multiple pathways can reduce the likelihood of patients developing 
resistance to the drug, severe side effects such as thrombocytopenia and 
peripheral neuropathy are associated with bortezomib treatment. In addition, 
bortezomib can exert off-target side effects that include the inhibition of serine 
proteases.  
 
Despite overall good clinical results, bortezomib resistance is frequently 
observed (Oerlemans et al. 2008). Given the first successful breakthrough of 
targeting the UPS pathway as a means to treat cancer, there has been a rapid 
development of second generation proteasome inhibitors to combat 
chemoresistance and reduce off-target side effects. Apart from boronates, 
expoxyketones and salinosporamides have been discovered to be effective 
classes of proteasome inhibitors (see Table 1.2). Both boronates and 
expoxyketones are synthetic inhibitors, which are typically composed of a 
short peptide that mimics the proteasome substrates and a pharmacophore that 
selectively binds to the active site of 20S proteasome proteases (Kisselev & 
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Goldberg 2001; Navon & Ciechanover 2009). Another chemical class of 
proteasome inhibitor are salinosporamides, naturally occurring proteasome 
inhibitors found in the Salinispora genus of marine bacteria. This inhibitor 
contains a γ-lactam-β-lactone bicyclic core (Potts et al. 2011). The second 
generation proteasome inhibitors are showing promising potential of being 
effective chemotherapeutic agents, with carfilzomib and Ixazomib being FDA-
approved drugs for the treatment of relapsed myeloma. Currently, there are at 
least 3 other second generation proteasome inhibitors undergoing clinical trials 
(Table 1.2) (Stintzing & Lenz 2014; Wang et al. 2014). 
 
 











































Boronates Phase I  
Oprozomib  
(ONX 0912) 
Epoxyketones Phase I  
Marizomib  
(NPI-0052) 




Another chemotherapeutic drug that targets the protein degradation pathway, 
with a different mechanism of action, is MLN4924. Discovered by 
Millennium Pharmaceuticals in 2009 (Soucy et al. 2009), this drug is currently 
in clinical trials phase 1/2 for the treatment of blood cancers and solid tumors 
(Soucy et al. 2010; Nawrocki et al. 2012). MLN4924 is a specific inhibitor of 
the Nedd8-activating enzyme, found in the upstream pathway that is required 
for the activation of CRL family (Brownell et al. 2010; Soucy et al. 2009). 
Although MLN4924 was initially found to disrupt S-phase cell cycle 
regulation leading to DNA damage and apoptosis, further mechanistic studies 
suggest that MLN4924 also exerts its anti-cancer activity via promoting 
senescence and autophagy (Zhao et al. 2012; Luo et al. 2012). 
 
1.7 Motivation and aim of PhD project 
The broad-spectrum nature of drugs targeting the proteasome pathway often 
leads to many undesirable adverse events. This is exemplified by the severe 
side effect of thrombocytopenia and peripheral neuropathy through the use of 
bortezomib. Therefore, the discovery and development of a more targeted drug, 
specific to individual CRLs, could limit the disruption of multiple signaling 
pathways and mediate the specific degradation of tumor suppressors, and/or 
enhance degradation of oncogene proteins. This in turn could reduce side 
effects and achieve greater efficacy in clinical use. It is hence not surprising 
that MLN4924 has gathered interest as an upstream inhibitor of the 





As explored in Section 1.5, there is a relationship between aberrations in CRL 
activity and tumor development & progression in both animal models and 
humans. Therefore, given the wide disease implications of CRL dysfunction 
and the potential of various CRLs as a suitable target for cancer treatment, it is 
crucial to obtain a better mechanistic understanding of CRL function and 
regulation and to identify and characterize novel substrates degraded by CRLs. 
 
Therefore, the aim of this PhD research project is (i) to characterize the 
regulation of the potential CRL substrate Insulin Receptor Substrate 1 (IRS1) 




2.0 Materials and Methods 
2.1 Plasmid constructs 
Mouse pcDNA3.1-Myc-His-IRS1 was a gift from Jazwinder K. Sethi 
(Nawaratne et al. 2006). Human insulin receptor tagged with GFP (hIR-GFP) 
was a gift from Joseph Bass (Addgene plasmid # 22286). 
 
SOCS1 was amplified from cDNA using  
F: 5’-AGAAGCTTGCCACCATGGTAGCACACAACCAG-3’ and  
R: 5’-AGTCTAGATAAATTCTGGAAGGGGAAG -3’ 
and inserted into N-terminally tagged Flag-pcDNA3 plasmid using HindIII 
and XbaI restriction sites. 
 
SOCS3 and SOCS6 was amplified from MGC clones (IMAGE ID 30333577 
and IMAGE ID 3917519 respectively) and cloned into C-terminally tagged 
Flag-pcDNA3 plasmid using KpnI and SacII restriction sites. The primers 
used are: 
SOCS3 F: 5’-AGGGTACCGCCACCATGGTCACCCACAGCAAG -3’ 
SOCS3 R: 5’-AGCCGCGGAAGCGGGGCATCGTACTG -3’ 
SOCS6 F: 5’-AGGGTACCGCCACCATGAAGAAAATTAGTCTT -3’ 
SOCS6 R: 5’-AGCCGCGGGTAGTGCTTCTCCTGTAA -3’ 
 
GST-Skp2ΔN-Skp1ΔΔ-pGEX4T1 plasmid for recombinant Skp1/Skp2 
protein expression was a kind gift from Brenda Schulman (Li et al. 2005). HA 






R: 5’-AGCTCGAGTCATAGACAACTGGGCTTTTGCAG -3’ 
 
Skp1b-V5-pcDNA3, HA-Skp2-pcDNA3.1/zeo, Cullin5-V5-pcDNA3, Cullin1-
Flag-pcDNA3 plasmids were previously generated by lab members.  
 




and inserted into the C-terminally tagged V5-pcDNA3 plasmid. 
 
N-terminal V5 tagged Skp1a and tetracycline inducible Skp1a-V5-
pcDNA4/TO were cloned from Skp1a-V5-pcDNA3. N-terminal V5 tagged 
Skp1b and tetracycline inducible Skp1b-V5-pcDNA4/TO were cloned from 
Skp1b-V5-pcDNA3. 
 
SGT1 DNA sequence was ordered from Shinegene Company and amplified 
using the following primers: 
F: 5’-AGGGTACCATGGCGGCGGCTGCAGCA -3’ 
R: 5’-AGGGGCCCTTAGTACTTTTTCCATTC -3’ 




All the cloned plasmids were confirmed by DNA sequencing. 
 
2.2 Cell culture and transfection 
Human embryonic kidney 293 (HEK293), HEK293T, human cervix 
adenocarcinoma (HeLa), and mouse preadipocyte (3T3-L1) cells were 
maintained in Dulbecco's modified Eagle's medium (DMEM). Human colon 
carcinoma (HCT116), human mammary carcinoma (MCF7) and rat hepatoma 
(Fao) cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium. All cells were cultured at 37 °C under 5% CO2. All cell culture 
media were supplemented with 1% penicillium/streptomycin (Invitrogen), 
10% fetal bovine serum (FBS) and 2 mM L- glutamine. Transient transfection 
was performed using GeneJuice transfection reagent (Novagen) according to 
the manufacturer's instructions.  
 
siRNA-mediated silencing was performed using Lipofectamine RNAiMax 
reagent (Invitrogen) according to the to the manufacturer's instructions. The 
following siRNAs were used: Cullin5 siRNAs (HSC.RNAI.N3478.10.3 and 
HSC.RNAI.N3478.10.4; Integrated DNA Technologies), Skp2 siRNA 
(A51321; Ambion) and Skp1 siRNA (Integrated DNA Technologies) with the 
following sequence: 
5’-rUrUrC rArUrC rArUrC rCrArU rUrCrC rCrArA-3’ 







For V5-IP and myc-IP, V5 or myc antibody respectively was coupled to 20 μl 
of protein G-Sepharose (Amersham Biosciences). For Flag-IP, 20 μl of Flag-
agarose (Sigma) was used. Cell lysate was precleared and added to beads. The 
samples were tumbled for 1 hours at 4°C. Subsequently, the beads were 
washed with low salt NP40 lysis buffer (50 mM NaCl, 0.5% NP-40, 5% 
glycerol, 0.5 mM EDTA, 50 mM Tris (pH 7.5)), twice in high salt NP40 lysis 
buffer (0.4M NaCl, 0.5% NP-40, 5% glycerol, 0.5 mM EDTA, 50 mM Tris 
(pH 7.5)), and the fourth time in low salt NP40 lysis buffer. The 
immunoprecipitated proteins were then denatured in SDS sample buffer and 
subjected to Western blot analysis. 
 
2.4 Recombinant protein expression 
Recombinant Skp1/Skp2 protein expression and purification was described 
previously (Li et al. 2005). Briefly, the plasmid was transformed in BL21 
competent cells and single colony was grown overnight at 200rpm 37 ºC. 
Large scale expression was performed using 200 ml LB media containing 150 
µg/ml ampicillin and 2ml overnight culture. Once OD600 reached 0.8, 1 mM 
of IPTG was added and cells were shaken at 200 rpm 16 ºC for 20 hours. Cells 
were harvested by centrifuging and pellet was frozen at -80 ºC. Bacteria cells 








Cells were washed with ice-cold 1X PBS and lysed with triton lysis buffer (25 
mM Tris-HCl (pH 7.5), 100 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 20 
mM NaF, 1 mM sodium orthovanadate, 20 mM sodium β-glycerophosphate, 
10 mM sodium pyrophosphate, 0.5% Triton X-100 and protease inhibitor 
cocktail (Roche Diagnostics) containing 0.1% -mercaptoethanol. Lysates 
were precleared using centrifugation and equal amounts of proteins were 
determined using the Bradford protein assay and loaded. The following 
antibodies were used: mouse monoclonal anti-glyceraldehyde-3-phosphate 
dehydrogenase (G8140–04; U.S. Biological), mouse monoclonal anti-α-
tubulin (236–10501; Molecular Probes), mouse monoclonal anti-myc (2276S; 
Cell Signaling Technology), mouse monoclonal anti-V5 (MCA1360; AbD 
Serotec), rat monoclonal anti-HA (3F10: Roche Applied Science), mouse 
monoclonal anti-Flag M2 (F-3165; Sigma-Aldrich), rabbit monoclonal anti-
phospho-AKT Thr308 (244F9; Cell Signaling Technology), mouse 
monoclonal anti-phospho-AKT Ser473 (587F11; Cell Signaling Technology), 
rabbit polyclonal anti-IRS1 (sc-7200; Santa Cruz Biotechnology), rabbit 
polyclonal anti-IRS2 (06-506; Upstate), rabbit polyclonal anti-Cullin5 (sc-
13014; Santa Cruz Biotechnology), mouse anti-p27 (610241; BD 
Biosciences), rabbit polyclonal anti-Skp1 (2156S; Cell Signaling Technology), 
mouse monoclonal anti-Skp1 (sc-5281; Santa Cruz Biotechnology), rabbit 
polyclonal anti-Skp2 (4358S; Cell Signaling Technology), Western blots 





2.6 RNA extraction and real-time qualitative PCR 
RNA extraction from cells was carried out using TRIzol reagent (Invitrogen). 
Real-time quantitative PCR was performed on the iQ5 Optical System 
Software Version 2.0 (Bio-Rad) using iScript™ One-Step RT-PCR Kit with 
SYBR® Green (Bio-Rad). The following primer pairs were used, and 
designed using primer express software (Applied Biosystems):  
 
human Skp1a (F: 5’-TGACCAAGGAACACTTTTTGAACTC-3’,  
R: 5’-TGTGTGCTACCTACCTGGGCTT-3’),  
 
human Skp1b (F: 5’-TGACCAAGGAACACTTTTTGAACTC-3’,  
R: 5’-TCTCTTTGCGTACCTGGGCTT-3’),  
 
human Skp1-V5 (F: 5’-TGACCAAGGAACACTTTTTGAACTC-3’,  
R: 5’-CCGAGGAGAGGGTTAGGGATAG-3’)  
 
human β-actin (F: 5’-GCCGACAGGATGCAGAAGGAGATCA-3’,  
R: 5’-AAGCATTTGCGGTGGACGATGGA-3’) (Wong & Hagen 2013) 
 
2.7 Immunofluorescence staining 
Cells were fixed with 4% formaldehyde for 15 minutes. The cells were 
subsequently permeabilised with PBS + 0.2% Triton X-100 and blocked with 
PBS + 0.05% Tween20 + 5% FBS. 1:1500 dilutions of both primary and 
secondary antibody were used. Subsequently, the coverslips were mounted 
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3.0 The role of Cullin5 E3 ubiquitin ligase in the regulation of Insulin 
Receptor Substrate 1 (IRS1) 
 
3.1 Introduction 
The insulin signaling cascade is an essential pathway that is responsible for 
cellular growth through the regulation of glucose transport and utilization as 
well as lipid and protein synthesis. Insulin is released from pancreatic beta-
cells in response to glucose and amino acids and mediates various direct and 
transcriptional responses in many organs. Despite the importance of insulin 
signaling in many physiological processes, the upregulation of the insulin 
signaling pathway has also been shown to contribute to cancer development 
(reviewed in Gallagher & LeRoith 2011).  
 
The activation of the insulin signaling pathway is mediated by three 
components: ligands such as insulin-like growth factor-1 (IGF-I), IGF-II and 
insulin, the insulin receptor (IR) and IGF-1 and IGF-2 receptors and a number 
of receptor binding proteins. One important IR binding protein is the insulin 
receptor substrate 1 (IRS1). Under physiological conditions, ligand binding to 
IR leads to conformational changes and tyrosine autophosphorylation on the 
IR. Phosphorylated tyrosines form docking sites for the IRS1 protein. Upon 
binding of IRS1, the protein itself becomes phosphorylated on tyrosine 
residues by the IR, leading to its activation. Of the activated signaling 
pathways downstream of IRS1, one of the most important pathways is the 
phosphatidylinositol 3-kinase (PI3K)/Akt cascade. p85 PI3K becomes 
activated upon binding to phosphorylated IRS1 via its Src Homology 2 (SH2) 
domain. This in turn leads to the activation of the downstream AKT pathway. 
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Consequently, there will be AKT-dependent activation of many targets, 
including the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) 
and the downstream serine/threonine kinase p70 S6 kinase 1 (S6K1). 
Activation of the mTORC1 pathway drives transcription, ribosome biogenesis 
and protein translation. Of note, an overexpression of IRS1 has been detected 
in various tumors and in breast cancer, this overexpression has been shown to 
lead to poor prognosis (Lee et al. 1999). 
 
Under physiological conditions, activation of the insulin signaling pathway 
results in a negative feedback loop that leads to the inhibition as well as 
proteasome-dependent degradation of IRS1. The degradation of IRS1 has been 
reported to be induced by different physiological signals in normal cells. One 
important mechanism is the phosphorylation of IRS1 on serine residues by 
S6K1. Serine phosphorylation of IRS1 prevents binding to IR (Paz et al. 1997) 
and has been reported to also promote proteasome-dependent degradation of 
IRS1 (Pederson, Kramer & Rondinone 2001). However, in cancer cells, IRS1 
protein upregulation can abrogate the negative feedback loop. This leads to an 
overall tumor-promoting effect on the cell that is mediated by various 
mechanisms, including an increase in cell proliferation, anti-apoptotic effects 
and reprogramming of cellular metabolism (reviewed in Mardilovich, 
Pankratz & Shaw 2009). 
 
One important molecular mechanism of activation or inhibition of the insulin 
signaling pathway is due to the binding of Src Homology 2 (SH2) domain-
containing proteins to phosphorylated IRS1. For instance, PI3K contains two 
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SH2 domains that recognize the phosphorylated tyrosine residues in IRS1. The 
binding of PI3K to IRS1 leads to activation of the insulin signaling pathway 
through AKT/mTORC1 proteins. Another protein family with an SH2 domain 
are the Suppressor of Cytokine Signaling (SOCS) proteins. The binding of 
SOCS proteins to phosphorylated IRS1 results in the inhibition of the insulin 
signaling pathway (Rui et al. 2002). 
 
Figure 3A. The insulin signaling pathway 
Upon ligand binding, the insulin receptor is autophosphorylated and 
subsequently, IRS1 protein docks onto the insulin receptor. IRS1 acts as a 
multisite docking protein for SH2-domain proteins such as PI3-kinase, which 
initiates the insulin signaling cascade, leading to activation of Akt and 
activation of the downstream effector mTORC1. SH2-domain containing 
SOCS proteins mediate a negative-feedback control mechanism that inhibits 
the insulin signaling cascade. SH2-domain SOCS proteins bind to IRS1 and 





Figure 3B. SOCS protein family 
SOCS1- SOCS7 and CIS family of protein with the central SH2 domain and a 
conserved SOCS box and the C-terminus of the protein (adapted from 
Alexander 2002) 
 
SOCS proteins form a family of proteins with eight members, SOCS1 to 
SOCS7 and cytokine-inducible SH2 domain-containing protein (CIS) (Hilton 
et al. 1998). This family of protein contains a central SH2 domain with a 
variable N-terminal domain and conserved C terminal SOCS box (Hilton et al. 
1998). The expression of SOCS proteins has been found to be upregulated in 
many cell lines and tissues in response to insulin (Banks et al. 2005), and the 
induction of SOCS proteins is shown to negatively regulate the insulin 
signaling pathway (Emanuelli et al. 2000). Of note, of the eight SOCS protein 
members, only SOCS1 and SOCS3 proteins have been reported to inhibit the 
insulin signaling pathway through the degradation of IRS1 (Rui et al. 2002).  
 
Although a number of mechanisms involved in the proteasomal degradation of 
IRS1 have been reported, the exact molecular mechanisms are not well 
characterized. We hypothesized that Cullin E3 ligases play a role in the 
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regulation of SOCS-dependent IRS1 stability based on three lines of evidence. 
Firstly, the SOCS box is similar to the α-domain of the pVHL protein (Babon 
et al. 2009). The pVHL protein associates with the Cullin2 and Cullin5 adapter 
proteins elongin B/C and function as a substrate receptor module. The pVHL-
elongin B/C complex recruits the substrate Hypoxia Inducible Factor-1α (HIF-
1α) to Cullin2 (Ohh et al. 2000). This leads to HIF-1α degradation and is 
known to be an important mediator of cellular oxygen sensing. Secondly, 
similar to pVHL, SOCS proteins are known to bind to elongin B/C in vitro and 
in vivo (Kibel et al. 1995).Thirdly, the SOCS protein contains a Cullin box, 
which can recognize and mediate binding to Cullin proteins. The Cullin box 
confers specificity for Cullin proteins, which is demonstrated by pVHL 
protein binding to Cullin2 and SOCS protein binding to Cullin5 (Kamura et al. 
2004). Taken together, these evidences suggest that SOCS proteins may 
regulate insulin signaling by recruiting IRS1 to the Cullin5 E3 ligase for 
ubiquitination and subsequent degradation. 
 
Cullin5 forms a scaffold for one of the family members of the Cullin RING E3 
ubiquitin ligase that assembles into a multi-subunit complex (Figure 1A in 
introduction). The Cullin5 protein binds to the substrate receptor module via 
its N-terminus and to the Rbx2 RING protein via its C-terminus. Rbx2 in turn 
functions to recruit the E2 ubiquitin conjugating enzyme. The substrate 
receptor module consists of the adaptor elongin B/C and different substrate 




Although studies have been conducted to show that SOCS proteins interact 
with elongin B/C, there is no direct evidence linking SOCS proteins to a 
functional role in recruiting and degrading IRS1 via CRL5. Thus, whether 
Cullin5 is directly responsible for the SOCS proteins mediated degradation of 
IRS1 remains unclear. Therefore, this chapter of the thesis aims to investigate 
Cullin5 and SOCS adaptor protein involvement in regulating 1) the basal IRS1 




3.2.1 Basal IRS1 protein stability  
We first wanted to determine the basal rate of IRS1 protein turnover. To this 
end, different cell lines were treated with the proteasomal inhibitor MG-132 
and the protein synthesis inhibitor cycloheximide. Upon new protein synthesis 
inhibition with cycloheximide, we observed a reduction of IRS1 protein 
concentration for HEK293T, HEK293, and HeLa cells. In contrast, 
cycloheximide incubation had a lesser effect on IRS1 protein abundance for 
MCF7 and 3T3-L1 cells. Blocking of protein degradation with MG-132 
resulted in a moderate IRS1 protein increase in HEK293T, HEK293, and Hela 
cell lines, but did not alter the IRS1 expression significantly in MCF7 and 
3T3-L1. Taken together, these results suggest that the stability of IRS1 protein 
is cell line dependent, with higher degradation rates in HEK293T, HEK293 





Figure 3.1. IRS1 basal protein stability in different cell lines. HEK293T, 
HEK293, Hela, MCF7 and 3T3-L1 cells were treated with the following 
drugs: cycloheximide (40 μM), MG-132 (20 μM), MLN4924 (3 μM) for 6 
hours. Cell lysates were analyzed by Western blotting. 
 
To determine if CRLs are involved in the degradation of IRS1 protein, we 
utilized MLN4924, an inhibitor of the Nedd8 E1 activating enzyme. As Nedd8 
E1 activating enzyme is required for the activation of CRL, treatment of cells 
with MLN4924 results in the inhibition of all CRLs, therefore leading to the 
accumulation of CRL substrates. As shown in Figure 3.2, MLN4924 treatment 
led to a marked accumulation of p27, HIF-1α, and Nrf2, which are bona fide 
substrates of CRL1, CRL2, and CRL3 respectively (Lee & Zhou 2010). Co-
treatment with the transcription inhibitor Actinomycin D did not alter the 
accumulation of substrates in the presence of MLN4924. Thus, this result 
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suggest that the effect of MLN4924 is independent of transcription, and we 
subsequently utilized MLN4924 to determine if IRS1 degradation is 
dependent on CRLs. 
 
Figure 3.2. Protein degradation of p27, HIF-1α, and Nrf2 is CRL-
dependent. HEK293T cells were pretreated with Actinomycin D (5 μg/mL) 
for 25 minutes before adding MLN4924 (3 μM) for 4 hours. Cell lysates were 
subsequently analyzed by Western blotting. 
 
We next determined if the basal IRS1 protein degradation is CRL-dependent. 
Therefore, HEK293 cells were treated with the protein synthesis inhibitor 
cycloheximide in the presence or absence of MLN4924. As shown in Figure 
3.3, no significant difference in IRS1 protein turnover was observed. Similarly, 
in the experiments shown in Figure 3.1, 6 hours treatment with MLN4924 did 
not cause a marked increase in IRS1 protein steady state levels in the tested 
cell lines with the exception of HEK293T cells. In HEK293T cells, MLN4924 
treatment caused a slightly less IRS1 protein accumulation compared to MG-
132 treatment. This is in contrast to MLN4924 treatment preventing bona fide 
CRL substrate p27 degradation to a greater extent than MG-132 treatment 
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(Figure 3.1). This indicates that MLN4924 is more effective in inhibiting CRL 
substrate degradation compared to MG-132. Therefore, our results show that 
even in HEK293T cells, CRL involvement in IRS1 stability is likely to be only 
partial. Taken together, the results suggest that CRLs do not play a major role 
in regulating IRS1 protein stability.  
 
 
Figure 3.3. MLN4924 does not alter IRS1 half-life in HEK293 cells. 
HEK293 cells were pretreated with MLN4924 (1 μM) for 2 hours followed by 
treatment with cycloheximide (40 μM) and cell lysis at the indicated time 
points. Cell lysates were subsequently analyzed by Western blotting. 
 
To specifically examine the role of Cullin5 in regulating IRS1 protein levels, 
we modified Cullin5 expression levels in HEK293 cells. We expect that if 
cullin5 regulates IRS1 protein levels, overexpression of Cullin5 will lead to a 
decrease in IRS1 protein levels and Cullin5 siRNA-mediated silencing would 




change in IRS1 protein abundance (Figure 3.4). Cullin5 was also knocked 
down using two different siRNAs. As seen in lanes 5-8, the siRNAs were 
effective in reducing the amount of both endogenous and transfected Cullin5 
protein. However, the IRS1 protein level was not significantly altered in the 
presence of Cullin5 siRNA.  
 
 
Figure 3.4. Cullin5 knockdown and overexpression does not alter IRS1 
protein expression in HEK293 cells. HEK293 cells were transfected with 20 
nM control or Cullin5 siRNA one day before transfection with Cul5-V5 
plasmid. Cells were lysed 24 hours after Cul5-V5 transfection. 
 
To confirm our previous result, HEK293 cells were treated with the protein 
synthesis inhibitor cycloheximide in the presence or absence of Cullin5 siRNA. 
Similar to what we observed in Figure 3.4, Cullin5 siRNA-mediated silencing 
did not alter IRS1 protein levels (lanes 1-4). Upon inhibition of new protein 
synthesis, IRS1 protein levels also did not decrease significantly. This result 






Figure 3.5. Basal IRS1 protein degradation is independent of Cullin5. 
HEK293 cells were transfected with 20 nM control or Cullin5 siRNA three 
days before 6 hours treatment with Cycloheximide (40 μM). Cells were lysed 
followed by Western blot analysis. 
 
Taken together, the results suggest that CRLs do not play a major role in the 
regulation of basal IRS1 protein levels. As it was reported that IRS1 
degradation can be induced through various signaling cascade in the cell, we 
next investigated whether the degradation is dependent on CRLs. 
 
 
3.2.2 Effect of mTOR on IRS1 protein stability 
It is known that IRS1 degradation can be induced through different signaling 
cascade in the cell. Therefore we next investigated whether cell signaling-
induced degradation of IRS1 is dependent on Cullin5. The degradation of the 
IRS1 protein has been reported to be induced by different cellular signaling 
pathways, including the mTOR/S6K1 pathway. The protein kinase S6K1 is a 
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downstream target of the mTOR complex I (mTORC1) and phosphorylates 
IRS1 on serine residues, leading to inhibition and degradation of the IRS1 
protein (Hiratani et al. 2005). Therefore, we next investigated the effect of 
mTOR/S6K1 signaling on IRS1 protein levels (Figure 3.6). To this end, we 
treated cells with the mTORC1 inhibitor rapamycin. As expected, 
phosphorylation of the mTORC1 downstream target p70 S6K1 was 
completely inhibited in the presence of rapamycin. We also observed a 
downward mobility shift in the IRS1 protein upon mTORC1 inhibition. This is 
indicative of reduced IRS1 phosphorylation. This result suggests that S6K1 
contributes to the basal phosphorylation of IRS1. However, the densitometry 
results from three independent experiments showed no difference in IRS1 
protein concentrations between control and rapamycin treated cells. Therefore, 
these results suggests that the mTOR/S6K1 pathway does not regulate IRS1 
basal protein stability although it affects the phosphorylation status of the 
IRS1 protein. 
 
It was previously reported that mTORC1 can be robustly activated upon the 
addition of cycloheximide (Finlay et al. 2006). This activation of mOTRC1 is 
likely due to cellular amino acids accumulation when there is a decrease in 
protein synthesis. The activated mTORC1 in turn would phosphorylate 
downstream targets such as S6K. As expected, addition of cycloheximide 
results in a marked increase in the active phosphorylated form of S6K1 
(Figure 3.6). It was also noted that cycloheximide lowered the mobility of 
IRS1, and this effect is likely due to S6K1-dependent IRS1 phosphorylation. 
Indeed, co-treatment of cells with cycloheximide and rapamycin prevented the 
36 
 
phosphorylation of both S6K and IRS1. Quantification of the IRS1 protein 
steady-state levels indicated that mTOR activation caused an approximately 
50% decrease in IRS1. This effect was partially prevented by rapamycin. Thus, 
IRS1 protein levels with cycloheximide increased from 46% in the absence 




Figure 3.6. Basal IRS1 protein degradation is independent of 
mTOR/S6K1 activity. Co-treatment with rapamycin (20 nM) or 
cycloheximide (40 μM) was performed in HEK293T cells for 6 hours followed 
by cell lysis and Western blot analysis. IRS1 protein abundance was 
determined by densitometry analysis. All forms of IRS1 (shifted and not 
shifted) were included in the densitometry analysis. The asterisk denotes that 




Taken together, our results demonstrate that under basal conditions in the 
presence of serum (to activate mTORC1), mTOR/S6K is unlikely to be 
involved in regulating IRS1 protein levels. However, the further activation of 
the mTOR/S6K pathway to higher levels may promote IRS1 protein 
degradation.  
 
3.2.3 Effect of TPA on IRS1 protein stability 
Phorbol ester (TPA) has been reported to negatively regulate IRS1 protein 
through the activation of the PKC pathway (Nawaratne et al. 2006). Therefore, 
to investigate IRS1 degradation mechanism upon PKC activation, we treated 
cells with 10 nM of TPA. As expected, we observed a marked reduction in 
IRS1 protein levels (Figure 3.7 lane 2). Treatment with Gö6983, a selective 
PKC inhibitor, reversed the TPA-induced degradation. 
 
 
Figure 3.7. PKC activation with TPA reduces IRS1 protein levels. 
HEK293T cells were preincubated with Gö6983 (5 nM) for one hour before 





To confirm that IRS1 protein stability is reduced in the presence of TPA, 
cycloheximide chase was conducted in the presence or absence of TPA. The 
half-life of IRS1 under TPA treatment was shorter compared to the control 
(Figure 3.8). Therefore, our results suggest that PKC activation mediates the 
reduction of IRS1 levels through enhancing protein degradation. 
 
 
Figure 3.8. TPA decreases IRS1 protein half-life. HEK293 cells were 
pretreated with 10 nM TPA for 1 hour followed by cycloheximide chase (40 
μM) for the indicated time before cell lysis. 
 
To manipulate IRS1 and identify the involved phosphorylation events, we 
investigated the effect of PKC activation on transfected IRS1. Opposite to 
what was observed for endogenous IRS1, transfected IRS1 showed an increase 







Figure 3.9. TPA increases transfected IRS1 protein levels. HEK293T cells 
were transfected with the respective amount of IRS1-myc plasmid. Cells were 
treated with TPA (10 nM) for 24 hours before cell lysis. 
 
To investigate whether this was a nonspecific effect of TPA on transfected 
proteins, we determined the endogenous and transfected levels of an unrelated 
protein, β-catenin, upon treatment with TPA. As seen in Figure 3.10, the 
endogenous β-catenin protein level remains unchanged upon TPA treatment. 
 
 
Figure 3.10. TPA has no effect on β-catenin. HEK293 cells were treated 
with TPA (10 nM) for 24 hours followed by Western blot analysis. 
 
To specifically determine if the CMV promoter of the IRS1 plasmid is 
affected by TPA in Figure 3.9, we used β-catenin which is cloned into two 
different plasmid backbone and promoters for our experiments. The CMV and 
EF2 promoter is present in pcDNA3 and pEF1 plasmid backbone, respectively. 
As seen in Figure 3.11, transfected β-catenin, regardless of the promoter types, 
was increased in the presence of TPA. We also observed that the effect of 





Figure 3.11. TPA upregulates transfected β-catenin. HEK293 cells were 
transfected with 0.5 μg of the indicated β-catenin plasmids. TPA (10 nM) was 
added for 24 hours followed by cell lysis. 
 
Taken together, the results confirmed that TPA has a nonspecific effect on the 
CMV and EF2 promoters of the plasmid. Therefore we were not able to 
further investigate and characterize transfected IRS1 degradation in the 
presence of TPA. As such, we investigated whether TPA-dependent IRS1 
degradation is dependent on CRL. 
 
 
3.2.4 Cullin5 is not involved in the TPA-induced endogenous IRS1 
degradation  
 
Previously, we have shown that the IRS1 protein half-life is reduced upon 
treatment of TPA (Figure 3.8). To further confirm that this reduction is due to 
degradation, cells were co-treated with TPA and the proteasome inhibitor MG-
132. We observed that the downregulation of IRS1 was inhibited when MG-
132 was present. Similar findings were also observed with co-treatment of 
TPA and MLN4924. We observed that MG-132 prevented the degradation of 
IRS1 protein in the presence of TPA to a greater extent compared to 
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MLN4924. This is in contrast to what was demonstrated in Figure 3.1, where 
MLN4924 prevented the degradation of bona fide Cullin substrate to a greater 
extent compared to MG-132. Therefore, our results show that the TPA-
dependent degradation of IRS1 is only partially dependent on Cullin E3 
ligases. 
 
Figure 3.12. CRLs are partially responsible for IRS1 degradation. 
HEK293 cells were treated with TPA (10 nM) for the 24 hours. Cotreatment 
with MLN4924 (3 μM) and MG-132 (20 μM) was carried out for 24 hours and 
6 hours respectively, before cell lysis. 
 
SOCS proteins have been reported to negatively regulate IRS1 protein (Rui et 
al. 2002). Given the suggested role of SOCS proteins as the substrate receptor 
of CRL5, we next determined the role of Cullin5 in IRS1 degradation in the 
presence of TPA.  
 
To evaluate the role of Cullin5 in TPA-mediated IRS1 degradation, cells were 
transfected with control or Cullin5 siRNA, and treated with TPA. Consistent 
with previous results, basal IRS1 levels did not change upon knockdown of 
Cullin5 (Figure 3.13 lanes 1-4). There was no effect on IRS1 protein levels 
upon Cullin5 knockdown in lanes 6-8, suggesting that Cullin5 does not play a 
role in the TPA-induced degradation of IRS1. In conclusion, these results 
42 
 
show that IRS1 protein degradation observed after TPA treatment is not 
dependent on Cullin5. 
 
 
Figure 3.13. Cullin5 does not mediate TPA-induced degradation of IRS1. 
HEK293 cells were transfected with 20 nM control or Cullin5 siRNA two 
days before treatment with TPA (10 nM) for 24 hours before cell lysis. 
 
 
3.2.5 Effect of overexpression of SOCS and human insulin receptor on basal 
IRS1 protein degradation 
 
To evaluate whether SOCS proteins negatively regulate basal IRS1 protein 
expression, cells were transfected with either 0.3 μg or 0.6 μg of SOCS1, 
SOCS3 and SOCS6. We observed that the IRS1 protein levels were not altered 






Figure 3.14. SOCS proteins do not play a role in the basal degradation of 
IRS1 protein. HEK293T cells were transfected with 0.3 μg or 0.6 μg of 
SOCS1, SOCS3 and SOCS6 plasmid as indicated. Cells were subsequently 
lysed followed by Western blot analysis. 
 
As previously published by Rui et al, the down-regulation of IRS1 through 
SOCS proteins was observed when the authors co-expressed the insulin 
receptor with the SOCS proteins (Rui et al. 2002). Thus, we first measured the 
half-life of IRS1 with overexpression of human insulin receptor (hIR-GFP) in 
both HEK293T and HEK293 cells. As expected, we observed two insulin 
receptor bands. The pro-form of the insulin receptor (220 kDa) is cleaved into 
α and β subunits. Only the pro-form and β subunit of insulin receptor was 
detected by the GFP antibody. There was no significant down-regulation of 
IRS1 under basal conditions, nor a significant change in the half-life of IRS1, 





Figure 3.15. Human insulin receptor does not play a role in the basal 
degradation of IRS1 protein. (A) HEK293T cells or (B) HEK293 cells were 
transfected with 0.6μg of empty vector (EV) or hIR-GFP respectively. Cells 
were treated with cycloheximide (40 μM) for the respective time points before 
lysis. Human IR-GFP was purchased from Addgene (plasmid 22286). 
Quantification of protein bands using densitometry was done, and results 
normalized to control is shown.  
 
We next investigated the effect of SOCS proteins and insulin receptor on basal 
IRS1 degradation by co-transfection of insulin receptor with either SOCS1, 
SOCS3 or SOCS6 and determining the effect on IRS1 protein levels. We 
observed that the basal IRS1 protein levels were not altered (Figure 3.16). 
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Taken together, these results show that human insulin receptor and SOCS 




Figure 3.16. Human insulin receptor coexpression with SOCS proteins 
does not play a role in the basal degradation of IRS1 protein. HEK293 
cells were co-transfected with 0.6μg of hIR-GFP and 0.3μg or 0.6μg of 
SOCS1, SOCS3 and SOCS6 plasmid as indicated. Cells were subsequently 




IRS1 protein turnover is known to be mediated by the ubiquitin-
dependent proteasome system (Briaud et al. 2005; Zhande et al. 2002). Several 
mechanisms involved in IRS1 protein degradation have been reported- 
SOCS1/3- Cullin5 (Rui et al. 2002), Fbw8-Cullin7 (Xu et al. 2008), muscle-
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specific Fbxo40-Cullin1 (Shi et al. 2011) and the muscle specific Casitas B-
lineage Lymphoma b (cbl-b) RING-E3 ligase (Nakao et al. 2009). These 
multiple degradation mechanisms may serve as different layers of spatial and 
temporal control in the cell and this study was focused on elucidating the 
degradation mechanism of IRS1 by the SOCS proteins. 
 
The basal IRS1 protein turnover was investigated and IRS1 protein was found 
to be more unstable in HEK293, HEK293T, and HeLa cells, and more stable 
in MCF7 and 3T3-L1 cells. It is possible that the post-translational 
modifications that are responsible for IRS1 protein ubiquitination and 
degradation are different in the various cell lines, and this may account for the 
differences in the protein stability. Differences in the expression levels or 
activities of E3 ligases targeting IRS1 may also account for the different 
turnover rates of IRS1 in these cell lines.  
 
SOCS1 and SOCS3 has been demonstrated to induce IRS1 degradation (Rui et 
al. 2002) and SOCS proteins can act as the substrate receptor of Cullin5 E3 
ligases. Therefore, we investigated whether the ubiquitination and degradation 
of IRS1 is mediated by SOCS proteins functioning as substrate receptors of 
Cullin5. Our results using Cullin5 siRNA-mediated knockdown and SOCS 
protein overexpression argue against this possibility. In addition, we also did 
not observe significant IRS1 protein level difference when we co-express with 
the insulin receptor. Thus, it is likely that other Cullin and non-Cullin based 
E3 ligases can mediate the basal IRS1 turnover in a SOCS protein-
independent manner.  
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IRS1 phosphorylation is important in the regulation of its protein stability. For 
example, mTOR/S6K mediates IRS1 phosphorylation and this results in a 
negative feedback regulation of the insulin signaling pathway. This negative 
feedback could be mediated by either the inhibition of the IRS1 protein 
activity and/or the degradation of IRS1 protein. Our results suggest that under 
basal conditions with serum present, mTOR/S6K might not play a role in the 
basal IRS1 degradation. However, when mTOR/S6K signaling is further 
activated, IRS1 protein becomes more unstable. 
 
It has been reported that protein kinase C α (PKCα)-mediated phosphorylation 
causes inhibition of IRS1 activity (Nawaratne et al. 2006). Therefore, we 
determined the effect of the PKCα activator phorbol ester TPA. We observed 
that the half-life of IRS1 is decreased upon addition of TPA, and the PKC 
inhibitor Gö8963 restored the IRS1 protein levels in the presence of TPA. 
Together, these results show that PKCα phosphorylation of IRS1 can 
negatively regulate IRS1 protein levels through degradation. To further 
characterize the molecular basis of this degradation and to identify potential 
phosphorylation sites and IRS1 ubiquitin modification, overexpression 
experiments with IRS1 mutants were planned. However, transfected IRS1 is 
upregulated in the presence of TPA and this is due to a nonspecific effect of 
TPA on the plasmid promoter, thus precluding these studies. 
 
We also determined the role of Cullin5 in mediating TPA-induced IRS1 
degradation by testing the effect of the NAE inhibitor MLN4924 and of 
Cullin5 siRNA-mediated gene silencing in TPA-treated cells. However, 
48 
 
Cullin5 knockdown did not restore IRS1 protein levels in presence of TPA. 
We also observed that MLN4924 only partially restores IRS1 protein levels in 
the presence of TPA. As it is unlikely that TPA-induced IRS1 degradation is 
regulated via more than one E3 ubiquitin ligase, the results we observe might 
be due to the following reasons: the partial rescue effect upon treatment with 
MLN4924 may be due to inhibition of basal IRS1 protein turnover, while the 
partial degradation mediated by TPA may be due to IRS1 degradation by a 
non-Cullin based E3 ubiquitin ligase. 
 
To conclude, our results indicate that IRS1 inhibition by SOCS proteins is not 
primarily mediated by SOCS protein function as the substrate receptor of 
Cullin5 E3 ligase. It is possible that SOCS proteins can act through other E3 















4.0 Regulation of Cullin1 E3 ligase (SCF) substrate receptor module 
 
4.1 Introduction 
As discussed in the general introduction (Section 1.41), Cullin1 E3 ubiquitin 
ligases are multisubunit comprising of the Skp1 adaptor protein and one of 69 
different substrate recognition subunit. One of the substrate recognition 
subunits, S-phase kinase-associated protein 2 (Skp2), has been found to be 
overexpressed in over 16 different tumor types such as colorectal, breast and 
gastric cancer (Hershko 2008) and has been suggested to function as an 
oncogene (Gstaiger et al. 2001). The Skp2 protein is part of the Cullin1 E3 
ligase (Figure 1A), which is also known as the Skp1-Cullin1-F-box (SCF) 
complex. Skp2 contains two domains: an F-box domain which mediates the 
binding to the Cullin1 scaffold protein through Skp1 protein, and a substrate 
binding domain that is responsible for recruiting a number of different 
substrates. Ubiquitination and degradation of Skp2 substrates can mediate 
opposing effect in the same pathway, as demonstrated by Skp2 mediating the 
degradation of both positive (Cyclin D and Cyclin E) and negative (p21 and 
p27) regulators of cell cycle progression. However, Skp2 overexpression in 
cancer has been linked to promoting cell cycle progression and tumorigenesis.  
 
One of the best characterized substrates of Skp2 is the cell cycle inhibitor 
p27Kip1 (p27) (Carrano et al. 1999). The physiological function of p27 is to 
bind and inactivate cyclinE-CDK2 (cyclin-dependent kinase 2) complexes, 
leading to inhibition of S-phase initiation. Overexpression of Skp2 in cancers 
has been shown to accelerate the degradation of p27. Thus, the lowered p27 
threshold cannot effectively inhibit S-phase initiation, leading to cell cycle 
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progression and tumorigenesis. Indeed, p27 protein levels have been found to 
be down-regulated in many cancers such as upper gastrointestinal tract, skin, 
haematopoietic malignancies, glioma and sarcoma. The p27 protein has also 
been suggested to have prognostic and diagnostic potential (Chu, Hengst & 
Slingerland 2008). 
 
Given its importance in tumorigenesis, p27 is an attractive target for cancer 
treatment. To date, there is no drug in the market that targets the p27 protein. 
However proteasome inhibitors, which are effective in the treatment of 
cancers, are believed to exert some of their effect via increasing p27 protein 
levels. Bortezomib, a 26S proteasome inhibitor that is currently in clinical use, 
has been shown to be effective in the treatment of multiple myeloma and 
mantle cell lymphoma. However, there are drawbacks in targeting the 
proteasome. One major obstacle is that the inhibition of the proteasome leads 
to the accumulation of many substrates. Stabilization of different substrates 
can lead to opposing effect on tumor growth. In addition, inhibiting the 
degradation of all proteasome substrates can lead to adverse side effects and 
toxicity. For instance, the undesired inhibition of RhoA and Bax protein 
degradation contribute to thrombocytopenia (low blood platelet count) (Shi et 
al. 2014; Murai et al. 2014; Nayak, Kulkarni & Dash 2013), occurring in 
14.4% to 28% of relapsed, refractory multiple myeloma patients dependent on 
the ethnic group (Richardson et al. 2003; Lin et al. 2014). Therefore, due to 
the nonspecific nature of proteasome inhibition, targeting of E3 ubiquitin 
ligases has been suggested as an alternative therapeutic strategy in cancer. 
This is because E3 ubiquitin ligases only target a subset of protein substrates 
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for proteasomal degradation, thereby potentially limiting unwanted side 
effects. 
 
One of the promising E3 ubiquitin ligase targets is the CRL. In fact, the CRL 
inhibitor MLN4924 is currently in phase 2 clinical trials for both solid and 
blood cancers. However, inhibition of CRLs is not without its own 
disadvantage. There are 7 subfamilies of CRLs that are responsible for the 
ubiquitination of numerous cellular substrates. Therefore, research has been 
focused on finding even more specific and upstream inhibitors that prevent the 
degradation of an even smaller subclass of substrates.  
 
In recent years, research has been shifting towards identifying inhibitors of 
specific CRLs. In order for a CRL to function as an E3 ligase that transfers 
ubiquitin to the substrate, a step-wise assembly is required for CRL’s 
activation (Figure 4A). As such, inhibiting any of these assembly processes 
can be a potential target. One of such processes is the substrate binding, in 
which p27 substrate is recruited to the substrate receptor for degradation. 
Another important assembly process is the binding of specific F-box proteins 
to the Cullin1 scaffold. It is likely that there are regulatory mechanisms that 
govern the docking of F-box proteins in the assembly of the SCF complex. 
Understanding these regulatory mechanism will help in devising strategies for 





Figure 4A. Current view of the SCF assembly process 
(A) Substrate is recruited to the SCF through the substrate binding assembly 
process. (B) Upon substrate recruitment to SCF, ubiquitination leads to the 
degradation of the substrate by the 26S proteasome. (C) F-box substrate 
receptor and Skp1 form the substrate receptor module, which dissociates from 
the Cullin1 scaffold. (D) A new substrate receptor module is recruited and 
binds to Cullin1 scaffold in a process called substrate receptor module 
exchange. 
 
In order to bind to CRL, the F-box substrate receptor must form a complex 
with the Skp1 adaptor protein, resulting in the formation of a substrate 
receptor module (Figure 1A). However, there are 69 different F-box proteins 
(Wang et al. 2014) but only one Skp1 adaptor, and currently, the 
stoichiometric relationship between the F-box and Skp1 protein in cells is not 
clear. When expressed in bacterial expression systems, F-box proteins are 
highly insoluble and require the co-expression of Skp1 for their correct protein 
folding. This suggests that Skp1 binding promotes F-box protein folding in 
mammalian cells and that the F-box substrate receptor proteins would be 
present in cells as a module together with the Skp1 adaptor protein. However, 
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it is currently not known whether F-box proteins always exist in a complex 
with Skp1 in vivo or alternatively, whether F-box proteins are also present in 
cells as monomers and can function in a Skp1-independent manner. 
 
As the Skp2 substrate receptor has been shown to have the greatest binding 
affinity for Cullin1 among the 69 F-box proteins (Lee et al. 2011), Skp2 was 
chosen as a model to study the regulation of the substrate receptor module. 
Using this model, we sought to determine 1) the ratio of Skp1 and Skp2 
protein in the cell, 2) if Skp2 F-box protein can exist in Skp1-independent 




4.2.1 Estimation of cellular Skp1/Skp2 protein levels 
In initial studies, we determined the effect of knocking down the SCF adaptor 
Skp1 and the substrate recognition subunit Skp2 on known SCFSkp2 substrates. 
Given that both Skp1 and Skp2 are essential subunits of the SCFSkp2 complex, 
a similar increase in the protein level of the substrate p27 would be expected. 
However, we only observed a robust accumulation of the p27 protein upon 
Skp2 knockdown and not Skp1 knockdown (Figure 4.1). A similar trend was 
observed for the SCFSkp2 substrate p21. As a positive control, cells were 
treated with the NAE inhibitor MLN4924, which prevents the degradation of 
all bona fide Cullin substrates. We noticed that p21 protein level increased to a 
greater extent upon treatment with MLN4924 compared to Skp2 siRNA 
transfection. This effect is likely due to fact that p21 can be ubiquitinated by 
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SCFSkp2 as well as a Cullin4-based E3 ligase (CRL4Cdt2). The latter would also 
be inhibited upon MLN4924 treatment, but not Skp2 knockdown. 
 
It appeared that the knockdown of Skp2 was more robust compared to Skp1. 
However, the degree of Skp1 knockdown is somewhat underestimated due to 
the longer exposure time of the Western blot. Furthermore, in contrast to Skp2 
silencing, knocking down Skp1 has almost no effect on p27 and p21 protein 
amounts. We therefore conclude that only knocking down the expression of 
the Skp2 F-box protein but not of the Skp1 adaptor protein robustly prevents 
the degradation of the p27 substrate. 
 
  
Figure 4.1. Steady state level of p27 is increased upon substrate receptor 
Skp2 knockdown. HEK293T cells were transfected with control (ctl), Skp1 or 
Skp2 siRNA as described in Materials and Methods. Cells were treated with 1 




Based on the results in Figure 4.1, we hypothesized that the cellular Skp1 
protein concentration is significantly higher than the Skp2 protein 
concentration. Therefore, upon knockdown of Skp1 there is still sufficient 
remaining Skp1 protein in the cell to mediate p27 degradation. In contrast, the 
cellular Skp2 concentration may be lower and limiting and thus, a decrease in 
the Skp2 protein concentration would prevent the ubiquitination and 
degradation of the p27 substrate. As such, we decided to quantify the cellular 
amounts of Skp1 and Skp2 proteins in the cell. Recombinant Skp1 and Skp2 
proteins were synthesized and purified using glutathione-sepharose matrix. 
The recombinant Skp1 and Skp2 proteins were used as protein standards, and 
by comparing between the known protein standard and whole cell lysates, we 
can determine the abundance of Skp1 and Skp2 protein in the cell (Figure 4.2 
and 4.3). 
 
Given that the Skp2 recombinant protein is truncated for solubility, and the 
Skp2 antibody recognizes the truncated region, we measured the expression of 
HA-Skp2 and compared to the endogenous Skp2 in HEK293T cells. 
Densitometric analysis of the bands were performed and the Skp1 and Skp2 
concentrations were estimated as 20.7908 pg and 5.0682 pg of protein 
respectively, normalized to 1 mg of total cellular protein. Given that the 
molecular weights of Skp1 and Skp2 are 18.66 kDa and 23.77 kDa 
respectively, there is 1.11 fmol of Skp1 and 0.21 fmol of Skp2 protein. As the 
number of molecules per mole is constant (Avogadro constant 
6.0221415×1023), our calculation demonstrates that there is five times lesser 
amount of Skp2 F-box protein compared to Skp1 in HEK293T cells. We also 
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compared known amounts of Hela, MCF7, HCT116 and HEK293 total cell 
lysate and found that the amount of Skp1 present in these cell lines was 
comparable to HEK293T (Figure 4.4). 
 
Figure 4.2. Skp1 quantification. Skp1 recombinant protein was purified 
using glutathione-sepharose as described in Materials and Methods. Known 
amounts of recombinant protein and cell lysate were loaded and analyzed 
using Western blotting. Recombinant Skp1 protein is truncated, lacking amino 
acid residues 38–43 and 71-82. 
  
 
Figure 4.3. Skp2 protein quantification. Skp2 recombinant protein was 
purified using glutathione-sepharose as described in Materials and Methods. 
Known amounts of recombinant protein and cell lysate were loaded and 




Figure 4.4. Skp1 protein amount in Hela, MCF7, HCT116 and HEK293 
cell lines. Skp1 recombinant protein was purified using glutathione-sepharose 
as described in Materials and Methods. Known amounts of recombinant 
protein and cell lysate (50 µg) were loaded and analyzed using Western 
blotting. Recombinant Skp1 protein is truncated, lacking amino acid residues 
38–43 and 71-82. 
 
As there are two Skp1 protein isoforms (Skp1a and Skp1b), we had to ensure 
that our quantification methods include both isoforms. However, we found 
that the protein expression of Skp1a is much lower compared to Skp1b (see 
chapter 5). As Skp1a is expressed at a negligible level compared to Skp1b, we 
did not consider Skp1a protein levels in our quantification. In conclusion, 
there is an approximately five fold higher protein level for Skp1 compared to 
Skp2 in HEK293T cells. 
 
In humans, Skp2 is one of approximately 70 F-box proteins, 42 of which are 
expressed in HEK293 cells (Lee et al. 2011). Among the expressed F-box 
proteins, Skp2 was found to be most abundantly associated with Cullin1. 
Nevertheless, based on the estimated cellular ratio between the Skp1 and Skp2 
protein concentration and the number of other F-box proteins, it appears 
unlikely that all Skp2 protein is bound to Skp1. We therefore hypothesized 
that the association between Skp1 and Skp2 is dynamic and that a significant 
non-Skp1 bound pool of Skp2 exists in the cell. This could also explain the 
lack of effect of Skp1 knockdown on SCFSkp2 substrate levels. Thus, upon 
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Skp1 knockdown, Skp2 proteins can bind to the remaining Skp1 proteins to 
mediate substrate ubiquitination. We therefore set out to determine whether 
Skp2 can exist as a non-Skp1 bound protein in cells. Subsequently, we also 




4.2.2 Determining the amount of Skp1-bound and -unbound Skp2 protein 
Based on the known instability of F-box proteins in the absence of Skp1 in 
bacterial expression systems and studies suggesting similar relationships in 
mammalian cells (Yoshida, Murakami & Tanaka 2011), it is usually assumed 
that Skp1 and Skp2 proteins always exist in a heterodimeric form. Hence, we 
tried to determine if Skp2 is indeed always bound to Skp1 or can exist in a free 
form. 
 
We planned to use immunoprecipitation of Skp1 to determine how much of 
the cellular Skp2 protein exists in a Skp1-bound form. Hence, we tested 
whether the available Skp1 antibody was suitable for immunoprecipitation. 
Immunoprecipitation was performed on whole cell lysate using either control 
or Skp1 antibody. We observed a faint band for Skp1 in the 
immunoprecipitate (Figure 4.5 lane 2), while most of the Skp1 protein in the 
cell lysate was not captured by the antibody and remained in the post-IP lysate 
fraction (lane 4). This suggests that the Skp1 Cell Signaling antibody is not 




Figure 4.5. Skp1 antibody is not suitable for immunoprecipitation. 
HEK293T cell lysate was collected and subjected to immunoprecipitation (as 
described under Materials and Methods) using 2.5 µg of control or Skp1 Cell 
signaling antibody followed by Western blot analysis. The asterisks denote 
immunoglobulin heavy chain. 
 
As an alternative approach to determine to what degree Skp2 exists in a Skp1-
bound form, we used V5 epitope-tagged Skp1 protein. We transfected a Skp1-
V5 encoding plasmid and performed an immunoprecipitation experiment to 
determine endogenous bound Skp2 protein levels (Figure 4.6). The ratio of 
immunoprecipitated Skp2 (lane 3) to Skp2 present in the lysate (lanes 6 and 9) 
can be compared to that of Skp1 in the immunoprecipitate (lane 3) versus cell 
lysate (lanes 6 and 9). A similar ratio would suggest that most of the cellular 
Skp2 coimmunoprecipitates with Skp1 and is hence bound to cellular Skp1. In 
contrast, if the amount of immunoprecipitated Skp2 is very low, this would 
suggest that a large amount of cellular Skp2 exists in a free, not Skp1-bound 
form. Using the V5 antibody, we observed a strong band for Skp1 in the 
immunoprecipitate (Figure 4.6 lane 3), with Skp1 protein markedly depleted in 
the cell lysate after incubation with antibody (compare lane 6 versus lane 9). 
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This showed that transfected Skp1-V5 was efficiently immunoprecipitated. 
When blotting cell lysates with Skp1 antibody, we observed three bands, with 
the lowest band corresponding to endogenous Skp1 protein and the middle and 
top band presumably corresponding to transfected Skp1 protein. Of note, the 
two bands corresponding to transfected Skp1 protein were markedly more 
abundant compared to endogenous Skp1. Surprisingly, only the lower 
transfected Skp1 band was detected in the V5-Skp1 immunoprecipitate (lane 
3), while the higher molecular weight band was absent. The identity of this 
higher molecular weight band and the reason for the inability to be 
immunoprecipitated with V5 antibody is currently not clear. 
 
When we measured Skp2 binding, we observed only a faint band in the V5-
immunoprecipitate (lane 3). This suggests that only a small proportion of Skp2 
is bound to V5-Skp1. As mentioned above, the protein expression of 
transfected Skp1-V5 is in significant excess compared to endogenous Skp1 
protein (see high exposure Skp1 blot in Figure 4.6). Hence, the detected 
amount of Skp1-bound Skp2 in Figure 4.6 is likely still an overestimation. 
Therefore, the results suggest that the majority of Skp2 is in the free form and 






Figure 4.6. The majority of endogenous Skp2 protein exists in a non-Skp1 
bound form. HEK293T cells were transfected with either eGFP or Skp1-V5 
plasmid. Cell lysate was collected and equal amounts of protein were 
subjected to V5-immunoprecipitation. The asterisk denotes immunoglobulin 
heavy chain. 
 
To confirm these findings, we transfected cells with HA-Skp2 and Skp1-V5 
and measured the binding of transfected Skp2 to the immunoprecipitated Skp1 
(Figure 4.7). We observed a significant amount of HA-Skp2 in the Skp1-V5 
immunoprecipitate (lane 3). However, the amount of HA-Skp2 present in the 
lysate in lane 9 (which corresponds to 3% of the IP input) did not change 
significantly after performing the immunoprecipitation (i.e. the abundance of 
HA-Skp2 in the Pre-IP lysate (lane 9) and the Post-IP lysate (lane 6) was not 
significantly different). Therefore, consistent with the previous experiment, 
only a low amount of transfected Skp2 is bound to Skp1-V5. Taken together, 





Figure 4.7. The majority of transfected HA-Skp2 protein does not bind to 
Skp1-V5. HEK293T cells were transfected with HA-Skp2 and Skp1-V5 
plasmid as indicated. Cell lysate was collected and equal amounts of protein 
were subjected to V5-immunoprecipitation. The asterisk denotes 
immunoglobulin heavy chain. 
 
To rule out the possibility that Skp1 and Skp2 dissociate during the 
immunoprecipitation process, we performed a time course experiment, 
whereby we incubated the cell lysates with the V5 antibody conjugated 
sepharose beads for different times (5 minutes, 15 minutes, 60 minutes and 
120 minutes), and observed binding of HA-Skp2 to Skp1-V5. As observed 
from the Western blot analysis, after 5 minutes of immunoprecipitation a 
strong band for Skp1-V5 was detected (Figure 4.8). The signal increased 
further from 5 to 60 minutes, after which the signal then reached a plateau. 
This suggests that after 60 minutes, no additional binding of Skp1 occurs. The 
co-immunoprecipitated HA-Skp2 protein mirrored the time-dependent 
accumulation of Skp1-V5 in the immunoprecipitate (an increase in HA-Skp2 
protein binding up to 60 minutes and no further increase thereafter). We also 
observed the same trend for endogenous Skp2 binding to Skp1-V5 (results not 
shown). These results suggest that there is no dissociation between Skp1 and 
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Skp2 protein over the typical one hour immunoprecipitation period used in the 









Figure 4.8. Skp2 remains stably bound to Skp1 during the course of the 
immunoprecipitation. (A) HEK293T cells were transfected with HA-Skp2 
and/or Skp1-V5 plasmid as indicated. Cell lysate was collected and equal 
protein amount was subjected to V5-immunoprecipitation for the indicated 





4.2.3 Regulation of Skp2 cellular abundance 
Previously, we have found that only a minor portion of cellular Skp2 exists in 
a Skp1-bound form. It is hence possible that the binding of Skp2 to Skp1 plays 
a regulatory role that controls Skp2 protein stability. We thus first determined 
whether the half-life of Skp2 protein is altered when the cellular Skp1 protein 
levels are reduced. Cells were transfected with control or Skp1 siRNA 
followed by cycloheximide chase to prevent new protein synthesis and 
measurement of Skp2 protein turnover through Western blot analysis. 
Although there was an effective reduction in Skp1 protein (Figure 4.9 lanes 5 
to 8), we did not observe a significant change in the Skp2 protein half-life 
compared to the cells transfected with control siRNA. As expected, the 
SCFSkp2 substrate p27 was rapidly turned over in the presence of protein 
synthesis inhibitor cycloheximide (lanes 1 to 4). Consistent with Figure 4.1, 
siRNA-mediated silencing of Skp1 did not alter p27 protein half-life and this 
provides further evidence that knocking down of Skp1 does not affect p27 
protein stability. In conclusion, knockdown of Skp1 does not affect the protein 






Figure 4.9. No significant change in Skp2 basal protein stability in the 
absence of Skp1. HEK293T cells were transfected with control (ctl) or Skp1 
siRNA as described in Materials and Methods. Cells were treated with 40 µM 
cycloheximide (CHX) for the indicated times prior to cell lysis. Equal protein 
amounts were subjected to Western blotting. Statistical analysis showed no 
significant change between control and Skp1 siRNA for all time points. 
  
As discussed above in the chapter introduction, binding of Skp2 to Skp1 may 
be important for proper folding of Skp2. We therefore investigated the effect 
of overexpression and siRNA mediated knockdown of Skp1 on the amount of 
Skp2 that accumulated in the Triton X-100-insoluble cellular fraction. In the 
experiments in Figure 4.10, cells were transfected with Skp1-V5 and the 
amount of endogenous (Figure 4.10a) and transfected (Figure 4.10b) Skp2 in 
the triton-soluble and -insoluble fraction of the cell lysate was analyzed by 
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Western blotting. As shown in Figure 4.10a, when Skp1 was overexpressed 
there was only a slight increase in the soluble Skp2 and a small decrease in 
insoluble Skp2. Similar result was also observed for HA-Skp2 when we 






Figure 4.10. Effect of Skp1 overexpression on the triton-soluble and -
insoluble Skp2 pool. HEK293T cells were transfected with (A) Skp1-V5 or 
with (B) Skp1-V5 and HA-Skp2 as indicated. Cells were lysed and the lysates 
pre-cleared by centrifugation. The supernatant containing the triton-soluble 
protein fraction was separated from the pellet, containing the insoluble protein 
fraction. The insoluble fraction was boiled in the presence of sample loading 
dye. Volumes corresponding to equivalent amounts of starting material were 





















We next carried out siRNA mediated silencing of Skp1. The soluble protein 
levels of both endogenous and transfected Skp2 decreased upon Skp1 
knockdown (Figure 4.11 lanes 3 and 5). Of note, we did not observe an 
increase, but in fact a decrease in the insoluble pool of Skp2 when Skp1 was 
knocked down. This argues against a role for Skp1 to promote proper folding 




Figure 4.11. Effect of Skp1 knockdown on the triton-soluble and -
insoluble Skp2 pool. HEK293T cells were transfected with HA-Skp2 and co-
transfected with either control (ctl) or Skp1 siRNA, as indicated. The samples 
were prepared as described in Figure 4.10. Equal volumes were loaded for 
Western blot analysis. 
 
In summary, overexpression of Skp1 causes only a small decrease in insoluble 
Skp2 levels, whereas silencing of Skp1 expression does not lead to the 
expected increase in insoluble Skp2 protein. Taken together, these results 
suggest that Skp1 is not required to promote protein folding and solubility of 
Skp2. This is in contrast to the reported role of Skp1 in regulating the folding 
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of the F-box proteins Fbs2, Fbg5, Fbg3, and to a partial extent Fbg4 (Yoshida, 
Murakami & Tanaka 2011). 
 
 
4.2.4 Role of Skp1 in regulating Skp2 binding to cdh1 
Skp2 is known to be ubiquitinated by the APC/Ccdh1 E3 ligase. It was reported 
that transfected Skp2 with mutated or deleted F-box domain is subject to even 
greater cdh1-mediated degradation compared to wild-type Skp2 (Bashir et al. 
2004; Wei et al. 2004), thus it seems that the interaction between Skp2 and 
APC/Ccdh1 does not require that Skp2 is in a Skp1 bound form. We therefore 
decided to investigate whether the interaction between Skp1 and Skp2 limits 
the binding of Skp2 to cdh1. 
 
To determine the binding of endogenous Skp2 to cdh1 in the absence or 
presence of Skp1, cells were co-transfected with Skp1 or control siRNA and 
myc-cdh1 and an immunoprecipitation with Myc antibody was performed. 
However, we were unable to detect any coimmunoprecipitation of endogenous 







Figure 4.12. Coimmunoprecipitation of Myc-cdh1 and endogenous Skp2. 
HEK293T cells were transfected with myc-cdh1 plasmid and either control or 
Skp1 siRNA, as indicated. Cell lysate was collected and equal amounts of 
protein were subjected to myc-immunoprecipitation. 
 
A possible reason that may account for the absence of Skp2 binding to cdh1 
might be the low endogenous Skp2 protein levels. Therefore, we used an 
alternative approach to increase Skp2 protein abundance through 
overexpression. Cells were cotransfected with Skp1 siRNA and HA-Skp2 
followed by immunoprecipitation to determine Skp2 binding to cdh1. Myc-
cdh1 was effectively immunoprecipitated and we observed transfected HA-
Skp2 binding (Figure 4.13). In contrast, no Skp1 protein was detected in the 
Myc-cdh1 immunoprecipitate, suggesting that Skp2 interacts with APC/Ccdh1 
in a non Skp1-bound form. Although there was a robust decrease in Skp1 
protein levels when cells were transfected with Skp1 siRNA, Skp2 binding to 
cdh1 was not altered (compare lanes 4 and 5). The results suggest that Skp1 





Figure 4.13. siRNA mediated silencing of Skp1 did not affect the binding 
of HA-Skp2 to Myc-cdh1. HEK293T cells were transfected with Myc-cdh1 
or HA-Skp2 plasmids and control or Skp1 siRNA, as indicated. Cell lysate 
was collected and equal amounts of protein were subjected to Myc-
immunoprecipitation. 
 
To confirm these findings, we transfected HA-Skp2 and myc-cdh1, and 
cotransfected the cells with Skp1-V5. We observed that Skp2 binding to cdh1 
remained the same when increasing amounts of Skp1-V5 (from 0.2 µg to 0.8 
µg plasmid DNA) were transfected (Figure 4.14). This is consistent with our 
previous result, in which the knockdown of Skp1 protein expression did not 
change the levels of Skp2 binding to cdh1. Taken together, the results suggest 
that the binding of cdh1 to Skp2 is not regulated by the abundance of Skp1 
protein. These results are consistent with our earlier findings where we 






Figure 4.14. Skp1 overexpression did not affect the binding of HA-Skp2 to 
Myc-cdh1. HEK293T cells were transfected with Myc-cdh1 and HA-Skp2 
plasmids with varying amounts of Skp1-V5, as indicated. Cell lysate was 




4.3 Discussion  
The SCFSkp2 complex is the most abundant Cullin1-based E3 ligase complex 
in HEK293 cells (Lee et al. 2011). This greatly facilitated its early discovery 
and subsequent research into the structure and function of Skp2 (Zhang et al. 
1995; Yu, Gervais & Zhang 1998; Lisztwan et al. 1998). Many discoveries 
have been made in identifying the substrates that are degraded by Skp2 and 
the step-wise assembly required for the activation of the SCFSkp2 complex. In 
this study, we have used the Skp2 F-box protein as a model to further 
understand the regulation of the SCF substrate receptor module, consisting of 
Skp1 and one of approximately 70 different F-box proteins. Specifically, we 
addressed the question of what is the intracellular ratio between the Skp1 and 
Skp2 F-box protein expression. We also investigated whether binding of Skp1 




In our study, we observed that only the knockdown of Skp2 but not Skp1 
causes an increase in p27 and p21 protein levels. We also did not detect an 
increase in p27 protein half-life upon robust Skp1 knockdown. This is 
interesting as the Skp1 adaptor protein and Skp2 substrate receptor function in 
the same SCF complex. We hence hypothesized that the cellular concentration 
of Skp1 is significantly higher compared to Skp2 and that F-box substrate 
receptors such as Skp2, and not Skp1, are the limiting factor for protein 
degradation by SCF. Subsequent quantification of the Skp1 and Skp2 proteins 
demonstrated that the protein level of Skp1 is indeed higher than Skp2 
(approximately five fold). However, this excess of Skp1 is relatively moderate 
and given the large number of F-box proteins expressed in cells, it appears 
unlikely that there is a large Skp1 spare capacity that is sufficient to ensure 
that all substrate receptors are bound to it. We hence hypothesized that the 
interaction between Skp1 and Skp2 is dynamic and that a large cellular pool of 
Skp2 exists in a non-Skp1 bound form.  
 
We hence set out to carry out experiments to test this hypothesis and 
demonstrated that Skp2, despite having highest affinity to SCF among the 69 
different F-box proteins, exist predominantly in a non-Skp1 bound soluble 
form. This result is in contrast with the generally held view that F-box proteins 
exists largely as heterodimers with Skp1 in cells. In a study by Yoshida et al, 
the authors discovered a range of Skp1-dependencies for the proper folding 
and prevention of aggregation for the 5 F-box proteins investigated (Yoshida, 
Murakami & Tanaka 2011). On one end of the spectrum, Fbs1 protein does 
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not aggregate even in the absence of Skp1, indicating that Fbs1 does not 
require Skp1 to mediate correct conformation folding. The authors 
hypothesized that Fbs1 solubility in the absence of Skp1 is promoted through 
its interacting proteins. On the other end of the spectrum, Fbs2, Fbg3 and Fbg5 
are insoluble and form aggregates in the absence of Skp1. Thus, when these F-
box proteins were overexpressed, they became soluble only upon co-
expression of Skp1. Furthermore, our results indicated that the majority of 
Skp2 is in the triton-soluble cellular fraction. Knockdown of Skp1 lowered the 
soluble Skp2 concentration. Surprisingly, Skp1 knockdown also lowered the 
insoluble Skp2 pool. The reason for this observation is currently not clear, 
however, it is possible that the insoluble Skp2 reflects the soluble pool and 
that Skp1 knockdown lowers Skp2 expression by inducing co-translational 
protein degradation due to incorrect folding of Skp2. Co-translational protein 
degradation occurs when the polypeptide is degraded before it is able to 
correctly fold into a functional protein due to a degradation signal present in 
the nascent polypeptide. Nevertheless, the overall half-life of Skp2 is not 
affected by a reduction in Skp1 protein levels. Taken together, our results 
indicate that Skp2 exists to a large portion in a non-Skp1 bound form and that 
Skp1 binding is not required for Skp2 stability. It is possible that Skp1 binding 
is only required during co-translational protein folding of Skp2. It is currently 
not clear what mediates the solubility of non-Skp1 bound Skp2 protein in cells, 
but it is possible that the solubility is due to binding of chaperone proteins and 
other interacting proteins to elements found in the primary amino acid 




The Skp2 protein contains the substrate recognition domain as well as the F-
box domain. The F-box domain is located near the N-terminus (amino acid 
residues 107 to 167) and is recognized by the Skp1 adaptor protein to form the 
substrate receptor module of the SCF complex. Bashir et al. (2004) discovered 
that Skp2 protein also contains 5 putative Destruction boxes (D-box) motif. 
This D-box (RxxLxxxx[N/D/E]) can be recognized by the APC/C substrate 
receptor cdh1. Of the five D-boxes identified, only mutation of the most N-
terminal (amino acids 3-6 RxxL) D-box motif stabilizes Skp2 protein in the 
presence of cdh1 (Bashir et al. 2004). This result is also supported by another 
study in 2004, in which the authors demonstrated that the in vitro 
polyubiquitination of the same Skp2 D-box mutants by APC/Ccdh1 is prevented 
(Wei et al. 2004). Interestingly, Skp2 protein lacking the F-box domain (and 
therefore cannot form functional SCF complexes) is degraded when cdh1 is 
overexpressed (Bashir et al. 2004). This suggests that the destruction of Skp2 
by cdh1 might be regulated through competitive binding of APC/Ccdh1 and 
SCF to Skp2. We specifically tested whether cdh1 binding to Skp2 is affected 
by the Skp1 protein. Through immunoprecipitation experiments, we found that 
Skp1 protein levels do not regulate the binding of Skp2 to cdh1. This result is 
also consistent with our finding that Skp2 exist in a predominantly non-Skp1 
bound form, and therefore, the low ratio of Skp1 bound to Skp2 would not 
affect cdh1 binding.  
 
Our main conclusions are that Skp1 exists in moderate excess over Skp2 in 
cells. However, the majority of Skp2 exists in a non-Skp1 bound form in cells 
and Skp2 protein stability is not significantly affected by binding to Skp1. 
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Based on our results we propose the following model (Figure 4B). Skp2 and 
other F-box proteins exist to a large extent in a free non-Skp1 bound form. For 
Skp2 to function and promote substrate recruitment into SCFSkp2 complexes, it 
must be able to dynamically associate with Skp1 and compete with other F-
box proteins. As a result, knocking down Skp2 protein expression lowers the 
amount of Skp1-Skp2 complexes and leads to substrate stabilization. These 
results suggest that targeting the Skp1-F-box interaction may be a promising 
strategy for the inhibition of Cullin E3 ligases. Indeed, a Skp2 inhibitor 
targeting the interface of Skp1 and Skp2 protein demonstrates efficacy in 
suppressing human tumor xenografts in mice (Chan et al. 2013). 
 
 
Figure 4B. Proposed model of substrate receptor module assembly 
(A) F-box protein mainly exist in a free non-Skp1 bound form. (B) There is 
dynamic association of the 69 F-box proteins with the Skp1 adaptor protein. 
(C) Skp1-F-box substrate receptor module recruits substrate and (D) 




As there are over 69 different F-box proteins, and only a limited amount of 
Skp1, there must be tight control over the formation of active SCF complexes. 
Apart from recruitment of F-box proteins to Cullin1 to form a functional SCF 
complex, there are other proteins that bind to and regulate the activity of 
Cullin1. Targeting these proteins is another option to inhibit Cullin E3 ligases. 
One such protein is Cullin-associated and neddylation-dissociated protein 1 
(Cand1). The association of Cand1 to Cullin1 is prevented in two instances. 
Firstly, the conjugation of Cullin1 with the Nedd8 polypeptide induces a 
conformational change that prevents Cand1 from binding. Secondly, the 
binding of the F-box-Skp1 substrate receptor module is mutually exclusive to 
the binding of Cand1 as the Skp1 protein contains two loops that sterically 
clash with Cand1. Addition of Cand1 has been shown to promote the 
dissociation of F-box proteins from Cullin1 while not affecting the association 
rate of new F-box proteins (Pierce et al. 2013). It was also reported that Cand1 
dissociates from Cullin1 with the addition of the substrate receptor module, 
consisting of Skp1 and F-box protein. Cand1 dissociation from Cullin1 is 
dependent on the acidic internal loops (residues 38–43 and 71-82) on Skp1 
and the presence of a bound F-box protein (Schulman et al. 2000). Thus, Skp1 
loop mutants bound to F-box proteins or monomeric Skp1 is not able to 
dissociate Cand1. Cand1 has been suggested to be a substrate receptor 
exchange factor (SREF) that exists transiently in the dynamic Cullin1 complex. 
It is possible that Skp1 first binds to Cullin1 and only upon the recruitment of 
an F-box protein will Cand1 be displaced. There might be other additional 
exchange factors that facilitate the assembly and disassembly of the Cullin1 
complex that have yet to be discovered. It would be worthwhile to further 
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elucidate the mechanisms governing Skp1-F-box and exchange factor 











Characterisation of Skp1 isoforms 
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5.0 Characterisation of Skp1 isoforms 
 
5.1 Introduction 
Organisms such as the social amoeba Dictyostelium and the plant model 
organism Arabidopsis thaliana are known to harbor several Skp1 isoforms or 
Skp1-like proteins. These Skp1 proteins are found on different genes and 
chromosomes. However, in humans there is only 1 gene encoding for the two 
Skp1 protein sequences deposited in the NCBI database. The alternative 
splicing of the Skp1 gene results in two transcript variants - transcript variant 
1 encodes for a 2714 base pair mRNA and gives rise to a 160 amino acid 
protein (Skp1 isoform a), transcript variant 2 encodes for a 2028 base pair 
mRNA and gives rise to a 163 amino acid protein (Skp1 isoform b). In this 
chapter, Skp1 isoform a and Skp1 isoform b will be referred to as Skp1a and 
Skp1b, respectively. Both the Skp1a and Skp1b protein have been validated by 
NCBI and have undergone preliminary review by NCBI with at least 6 
independent cDNA clones. 
 
To date, studies conducted on the Skp1 protein have been carried out using the 
Skp1b isoform and there is currently no information on the function and 
regulation of Skp1a protein. Protein sequence alignment using EMBOSS 
Needle showed that the C-termini of Skp1a and Skp1b are different. Between 







Figure 5A. Protein alignment of Skp1a and Skp1b 
Protein sequences of Skp1a and Skp1b (NP_008861.2 and NP_733779.1 
respectively) were extracted from the NCBI database and analyzed using 
EMBOSS Needle pairwise sequence alignment software. “:” indicates 
conservation between side groups of strongly similar properties and “.” 
indicates conservation between side groups of weakly similar properties 
 
The difference in the C-termini of Skp1a and Skp1b is due to alternative 
splicing of the Skp1 mRNA transcript (Figure 5B). Both Skp1a and Skp1b 
share the first four exons. There is intron retention in the mature mRNA 
transcript of Skp1a, giving rise to a longer Skp1a mature mRNA transcript 
(Figure 5Bii). There are two TGA stop codons found in the mature Skp1a 
mRNA transcript- within the intron and in the fifth exon. As translation of the 
mature Skp1a mRNA transcript utilizes the TGA stop codon found within the 





Figure 5B. Schematic diagram of Skp1 mRNA transcripts and resultant 
protein sequences of Skp1a and Skp1b 
The mRNA sequences of Skp1a and Skp1b (NM_006930.3 and NM_170679.2, 
respectively) were extracted from the NCBI database and analyzed using 
EMBOSS Needle pairwise sequence alignment software. Exons are depicted 
as blue and green boxes. Intron is depicted as a yellow box. The Skp1 mRNA 
transcript undergoes alternative splicing (i), resulting in two mature mRNA 
transcripts (ii). Translation of the mature mRNAs give rise to the Skp1a and 
Skp1b proteins with differing C-terminal regions (iii). 
 
We decided to investigate the expression levels and potential functional 
differences between the two isoforms. In addition, this information was 
necessary in order to accurately quantify the cellular abundance of the Skp1 
protein in chapter 4. Therefore the aim of this chapter is to characterize Skp1a 
through 1) comparing the Skp1a and Skp1b expression levels and 2) 




5.2 Results  
5.2.1 Protein expression of Skp1a and Skp1b 
Since there is no available information about Skp1a, we first started by 
transfecting plasmids encoding for V5 tagged versions of Skp1a and Skp1b 
into cells and determining any difference in the protein expression. The DNA 
plasmids contained only the Skp1a or Skp1b open reading frames and were 
identical except for the different 3’ ends in Skp1a and Skp1b. Cells were 
transfected with equal amounts of Skp1a and Skp1b DNA plasmids and cell 
lysates subjected to Western blotting with Skp1 and V5 antibody. As seen in 
Figure 5.1, endogenous Skp1 was detected in all lanes, as indicated by the 
arrow. An additional band in cells transfected with Skp1b was detected and 
this band was at a higher molecular weight due to the V5 tag. In contrast, we 
did not observe any transfected Skp1a when using the Skp1 antibody (2156S; 
Cell Signaling). This could be due to either a low protein expression or the 
inability of the used Cell Signaling antibody to detect the Skp1a isoform. 
Therefore, we used V5 antibody to detect the transfected forms of the Skp1 
proteins, and we observed that there was a strong band for Skp1b and a very 
faint band representing Skp1a. This result shows that transfected Skp1a is 





Figure 5.1. Expression of Skp1a is markedly lower than Skp1b. HEK293T 
cells were transfected with 0.5 µg Skp1a-V5 and 0.5 µg Skp1b-V5. Equal 
protein amounts of cell lysate were analysed by Western blot using Cell 
Signaling Skp1 antibody (2156S; Cell Signaling Technology). 
 
The Cell Signaling Skp1 antibody detected only a single band of endogenous 
Skp1a. This may be due to the inability of the antibody to detect the Skp1a 
isoform. However, the low expression level of transfected Skp1a made it 
difficult to directly test whether the Cell Signaling Skp1 antibody is able to 
detect Skp1a. We hence used an alternative approach to detect isoform a. We 
first enriched Skp1a and Skp1b by IP with V5 antibody and subsequently 
blotted the immunoprecipitates with V5 and Skp1 antibodies. We observed 
good enrichment of both Skp1a and Skp1b in the V5 blot (Figure 5.2). 
However, there was no detection of Skp1a with the Cell Signaling antibody, 
suggesting that this antibody is unable to recognize Skp1a. This is consistent 
with the fact that the Cell Signaling antibody recognizes the C-terminus of the 
Skp1 protein, which is different between the two isoforms. 
 
We therefore used a different Skp1 antibody for Western blot analysis. Santa 
Cruz Skp1 antibody (Sc-5281) recognizes the N-terminus of the Skp1 protein, 
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and therefore we expect that this antibody can detect both isoforms. Indeed we 
detected a clear band for Skp1b. A faint band representing Skp1a was also 
detected in the V5 immunoprecipitate and is more visible under close 
inspection of film. As the transfected Skp1a protein is lower in abundance 
compared to transfected Skp1b, we compared the band ratio of 
immunoprecipitated Skp1a to Skp1b in the Western blot analysis by V5 and 
Santa Cruz Skp1 antibody. The similar intensity signal ratio suggests that the 
Santa Cruz antibody detects both Skp1a and Skp1b proteins. 
 
 
Figure 5.2. Both Skp1a and Skp1b can be detected with the Santa Cruz 
Skp1 antibody. HEK293T cells were transfected with 5 µg Skp1a-V5 and 2.5 
µg Skp1b-V5. The protein concentration of cell lysates was determined using 
the Bradford assay and equal protein amount subjected to 
immunoprecipitation as described in Materials and Methods. Western blot 
analysis was performed with V5 antibody, Cell Signaling Skp1 antibody 
(2156S; Cell Signaling Technology) and Santa Cruz Skp1 antibody (sc-5281; 
Santa Cruz Biotechnology). 
 
 
Next, we wanted to determine the ratio of endogenous Skp1a and Skp1b 
protein in the cell. Although the Santa Cruz Skp1 antibody detects both 
transfected Skp1a-V5 and Skp1b-V5 protein in the V5 immunoprecipitates, 
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numerous non-specific bands were observed when we used the antibody 
against whole cell lysate (Figure 5.3). Therefore we used an alternative 
approach whereby we first immunoprecipitated V5-Skp2 from cell lysate. We 
then determined the amount of the endogenous Skp1 isoforms that were bound 
to V5-Skp2. Western blot analysis was performed using Cell Signaling 
antibody (detects Skp1b only) and Santa Cruz Skp1 antibody (detects both 
Skp1a and Skp1b). As observed in lane 3, a clear band corresponding to 
endogenous Skp1 bound to immunoprecipitated V5-Skp2 was observed for 
both antibodies. The band detected with the Cell Signaling antibody 
corresponds to Skp1b. The band detected with the Santa Cruz antibody could 
in theory correspond to either Skp1a or Skp1b. We therefore cotransfected 
cells with untagged Skp1b (where indicated in the Western blot). We observed 
that untagged transfected Skp1b protein (lane 4) is of the same size as 
endogenous Skp1 (lane 3) as detected by the Santa Cruz antibody. This 
suggests that the Skp1 isoform detected by the Santa Cruz antibody is also 
Skp1b (Skp1a migrates faster compared to Skp1b; see Figure 5.2). 
Furthermore, if Skp1b is the predominant endogenous form found in the cell 
detected by both antibodies, the ratio between the Skp1 bands in lane 3 and 4 
for both the antibodies would be the same. On the other hand, if the Santa 
Cruz antibody were to detect Skp1a, there would be much less increase in 
signal upon Skp1b transfection compared with the Cell Signaling antibody. 
We observed a two fold increase for Skp1 detected by the Cell signaling 
antibody when comparing the Skp1 bands in lanes 3 and 4, and a similar 
increase was noted with the Santa Cruz antibody. A potential caveat in this 
experimental approach are differential affinities of Skp1a and Skp1b for 
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binding to Skp2. We indeed found that Skp1a binds less strongly to Skp2 
compared to Skp1b (see Figures 5.17 and 5.18). Nevertheless, taken together, 





Figure 5.3. Skp1b is the predominant Skp1 isoform in the cell. HEK293T 
cells were transfected with untagged Skp1b and HA-Skp2. Protein 
concentrations were determined by Bradford assay and equal protein amounts 
were subjected to immunoprecipitation as described in Materials and Methods. 
Western blot analysis with Skp2 antibody, V5 antibody, Cell Signaling Skp1 
antibody (2156S; Cell Signaling Technology) and Santa Cruz Skp1 antibody 
(sc-5281; Santa Cruz Biotechnology) were performed. The asterisk denotes 
immunoglobulin heavy chain. 
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5.2.2 Regulation of Skp1a and Skp1b protein levels 
We wanted to determine the basis for the low protein expression of transfected 
Skp1a. One possible explanation is that the Skp1a protein is unstable, 
therefore this would result in low protein expression. To test this, cells were 
transfected with either Skp1a or Skp1b plasmid and treated with different 
inhibitors (Figure 5.4). When we treated the cells with proteasome inhibitor 
MG-132, we did not observe a change in Skp1a protein levels. Similarly, 
treatment with NAE inhibitor did not alter Skp1a protein levels, suggesting 
that the low protein level of Skp1a was not due to ubiquitination and 
proteasome-dependent protein degradation. We also treated cells with protein 
synthesis inhibitor cycloheximide. If Skp1a is unstable, we would expect that 
inhibition of new protein synthesis results in a marked decrease in Skp1a 
protein levels. However, there was no change in Skp1a protein levels upon 
cycloheximide treatment for 6 hours. All these results suggest that the low 
abundance of Skp1a is not due to low protein stability. We also observed that 
Skp1b protein levels did not change in the presence of the various inhibitors, 
suggesting that Skp1b protein is relatively stable and does not undergo rapid 






Figure 5.4. Skp1a is not regulated via proteasome-dependent degradation. 
HEK293T cells were transfected with 0.5 µg of Skp1a-V5 and Skp1b-V5. 
Cells were treated with cycloheximide (40 µM), MG-132 (20 µM), and 
MLN4924 (1 µM) for 6 hours prior to cell lysis. Protein concentrations were 
determined by Bradford assay and equal protein amounts subjected to Western 
blot analysis as described in Materials and Methods using Santa Cruz Skp1 
antibody (sc-5281; Santa Cruz Biotechnology). 
 
Another pathway that can degrade and recycle proteins is the autophagy 
pathway. Given that our previous results show that Skp1a and Skp1b protein 
levels do not change in the presence of proteasome inhibitor, we hypothesized 
that autophagy may play a role in the low protein expression of Skp1a. To test 
this, cells were treated with the autophagy activator lithium chloride. As 
expected, upon activation of autophagy with lithium chloride, we observed a 
decrease in the levels of the autophagy marker LC3-II (due to increased 
autophagic flux). Compared to the control, Skp1a protein decreased (compare 
lane 2 and 3). Cells were also treated with autophagy inhibitors bafilomycin 
A1, chloroquine and ammonium chloride. As expected, all three inhibitors 
increased the cellular LC3-II concentration. However, we only observed a 
slight increase in the Skp1a level in the presence of bafilomycin A1 even 
though chloroquine and ammonium chloride caused the most pronounced 
increase in the autophagy marker LC3-II. Taken together, our results indicate 
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that the low protein expression of Skp1a is not due to autophagy-mediated 
degradation (Figure 5.5). 
 
Figure 5.5. Skp1a is not regulated by autophagy. HEK293T cells were 
transfected with 0.5 µg of Skp1a-V5 and Skp1b-V5, and treated with lithium 
chloride (10 mM), bafilomycin A1 (10 nM), chloroquine (50 µM) and 
ammonium chloride (20 mM) for 6 hours before western blot analysis using 
Santa Cruz Skp1 antibody (sc-5281; Santa Cruz Biotechnology). 
 
 
5.2.3 Protein folding status of Skp1a and Skp1b  
An alternative possibility for Skp1a low expression could be Skp1a intrinsic 
instability due to the different amino acid sequence in the C-terminus as 
compared to Skp1b. We hypothesized that this difference results in unfolding 
of Skp1a, consequently leading to cleavage of Skp1a protein and low protein 
expression in cells. 
 
We first performed bioinformatics analysis on the protein sequence of Skp1a 
and Skp1b to determine the protein disorder score of these two proteins. The 
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score reflects the propensity of the primary amino acid sequence to have a 
defined secondary structure. The PONDER-FIT is a web-based bioinformatics 
meta-predictor which is comprised of six individual predictors: PONDR® 
VLXT, PONDR® VL3, PONDR® VSL2, IUPred, FoldIndex, and TopIDP 
(Xue et al. 2010). To determine the disordered protein segments, the primary 
protein sequence of Skp1a and Skp1b (NP_008861.2 and NP_733779.1, 
respectively) was extracted from the NCBI database and analyzed by 
PONDER-FIT. The results show a plot of amino acid residue vs disorder score. 
The lower the protein disorder score, the greater is the propensity to have a 
defined secondary structure. When examining the C-terminal sequences of 
Skp1a and Skp1b from amino acid residue 150 onwards (i.e. the region in 
which Skp1a and Skp1b differ), we observed that both charts show a disorder 
score higher than 0.5 (Figure 5.6). This indicates that the Skp1a and Skp1b C-
termini are disordered. Comparing between Skp1a and Skp1b, the Skp1a 
disorder score is lower than Skp1b. This suggests that the C-terminus of Skp1a 













Figure 5.6. PONDER-FIT analysis of Skp1 proteins. The primary protein 
sequences of (A) Skp1a and (B) Skp1b (NP_008861.2 and NP_733779.1, 
respectively) were analyzed using PONDR-FIT. 
 
To confirm these findings, another meta-predictor, MetaPrDOS, was used for 
analysis. MetaPrDOS is comprised of eight individual predictors, of which 
seven are different from PONDER-FIT: PrDOS, DISOPRED2, DisEMBL™, 
DISPROT (VSL2), DISpro, IUpred, POODLE-S and DISOclust (Ishida & 
Kinoshita 2008). We observed similar overall trends when we used 
MetaPrDOS (Figure 5.7), suggesting that the previous results are accurate. 
Similar to the PONDER-FIT results, the disorder score for Skp1a is lower 

















different individual predictors, suggest that the C-terminus of Skp1a is less 




Figure 5.7. MetaPrDOS analysis of Skp1 proteins (A) Skp1a (B) Skp1b. 
The primary protein sequences of Skp1a and Skp1b (NP_008861.2 and 
NP_733779.1 respectively) were analyzed with MetaPrDOS. A false positive 
rate of 5% was utilized. 
 
 
To experimentally determine the relationship between the bioinformatics 
protein disorder score and protein intrinsic folding, trypsin digestion 
susceptibility assays were performed. Subconfluent cells were lysed and 
subjected to 80 ºC treatment to unfold the protein. Trypsin was subsequently 
added to cleave exposed lysine or arginine residues. A portion of lysate was 
collected at different time points during the trypsin digestion. We would 
expect that the more unfolded the protein is, the more cleavage of the protein 















trypsin-dependent digestion as shown by a faster decrease of the full-length 
protein compared to Skp1b.  
 
 
Figure 5.8. Skp1a is more susceptible to trypsin digestion than Skp1b. 
HEK293T cells were transfected with 1 µg Skp1a-V5 and 0.1 µg Skp1b-V5 
and lysed. Lysates were subjected to 80 ºC treatment for 15 minutes. Samples 
were subsequently placed on ice (4 ºC). Incubation with 0.01% Trypsin was 
performed on ice (4 ºC) for the indicated time. Equal aliquots of lysate were 
denatured for Western Blot analysis at the indicated time points.  
 
Incubation of cell lysates at higher temperature may lead to the formation of 
insoluble aggregates, which may interfere with trypsin dependent protein 
degradation (Major et al. 2006). Therefore, the experiment in Figure 5.8 was 
repeated without the heat pretreatment. As such, transfected cells were lysed 
and kept at 4 ºC for the typsin digestion assay. Similar to the previous result, 
we observed that the Skp1a protein abundance decreased at a faster rate 







Figure 5.9. Skp1a is more susceptible to trypsin digestion at 4 ºC than 
Skp1b. HEK293T cells were transfected with 1 µg Skp1a-V5 and 0.1 µg 
Skp1b-V5and lysed in lysis buffer lacking protease inhibitors. To perform the 
trypsin digestion assay, cell lysate samples were kept on ice (4 ºC). Incubation 
with 0.01% Trypsin was performed on ice (4 ºC) for the indicated time. The 
reaction was stopped at the indicated time-points. Equal aliquots of lysate 
from the different time points were analyzed by Western blotting.  
 
 
Taken together, these results show that although the protein sequence of Skp1a 
C-terminus is predicted to be less disordered, Skp1a is more susceptible to 
trypsin digestion and therefore likely to be less well-folded compared to 
Skp1b. This may at least partially account for the different protein expression 





5.2.4 Analysis of mRNA levels of endogenous Skp1a and Skp1b 
The findings in Sections 5.2.2 and 5.2.3 suggest that differences in post-
translational regulation of Skp1a and Skp1b are unlikely to completely 
account for the different expression levels of the two gene products. Hence, 
we examined the regulation of endogenous Skp1a and Skp1b at the mRNA 
level. To this end, mRNA of HEK293T, Fao and HCT116 cells was collected 
and real-time quantitative PCR was performed to determine the levels of 
Skp1a and Skp1b mRNA in cells (Figure 5.10). We observed that across the 
three different cell lines, Skp1b mRNA expression is higher than Skp1a. We 
also noted that the abundance of Skp1b mRNA differs between the cell lines. 
 
Figure 5.10. mRNA expression of Skp1a and Skp1b in various cell lines. 
HEK293T, Fao cells and HCT116 cells were grown on 60mm dishes and 
RNA was isolated. Real-time qualitative PCR was performed as described in 
Materials and Methods. 
 
The difference in the mRNA levels is most likely due to preferential splicing 
of Skp1b. However, in order to rule out that the low abundance of Skp1a is a 
consequence of rapid mRNA degradation, we compared the Skp1a and Skp1b 
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mRNA half-life. To this end, cells were treated with Actinomycin D for 0, 0.5 
and 1 hours and the mRNA was harvested. We observed that there was no 
marked difference in the rate of mRNA degradation between Skp1a and Skp1b 




Figure 5.11. Skp1a and Skp1b mRNA stability in HEK293T cells. Cells 
were grown on 60mm dishes and treated with Actinomycin (5 µg/ml) for the 
indicated times. Total RNA was isolated and Skp1a and Skp1b mRNA 
expression determined by real-time qualitative PCR, normalized to β-actin, as 
described in Materials and Methods.  
 
The above results indicate that the low expression of endogenous Skp1a 
compared to Skp1b is partially due to low mRNA levels, most likely due to 
preferential splicing of Skp1b. Nevertheless, we also noted a much lower 
protein abundance of transfected Skp1a compared to Skp1b when the 
expression of the Skp1a or Skp1b open reading frames was driven by a 
plasmid CMV promoter in transfected cells. The plasmids encoding for Skp1a 
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and Skp1b are identical with the exception of the DNA sequence encoding the 
extreme C-terminus of Skp1a and Skp1b. Thus, it would be expected that the 
plasmid driven mRNA expression of Skp1a and Skp1b would be the same. To 
confirm this and specifically quantify the amount of Skp1a and Skp1b mRNA 
that originated from the transfected plasmids, we used a reverse PCR primer 
that binds to the sequence encoding the C-terminal V5 epitope tag and 
performed real-time PCR. As seen in Figure 5.12, the mRNA expression of 
both Skp1a-V5 and Skp1b-V5 is indeed similar.  
 
 
Figure 5.12. mRNA of transfected Skp1a-V5 and Skp1b-V5. HEK293T 
were grown on 60mm dishes and transfected with 0.5 µg of Skp1a and Skp1b. 
Real-time qualitative PCR was performed using isolated total RNA as 
described in Materials and Methods. 
 
Our results above indicate that when the same concentrations of Skp1a and 
Skp1b encoding DNA plasmids were transfected into cells, the protein 
expression of Skp1b was markedly higher. This effect was not due to 
differences in the transfected Skp1a and Skp1b mRNA levels or regulation by 
the ubiquitin-proteasome and autophagy pathways (Chapter 5.2.2). We 
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therefore tested whether different protein translation efficiencies of the Skp1a 
and Skp1b mRNA account for the observed differences in protein expression. 
This may be due to differential binding of RNA binding proteins or 
microRNAs to the 3’end of the Skp1a and Skp1b mRNA. To test for different 
protein translation efficiencies, the Skp1a-V5 and Skp1b-V5 open reading 
frames were transferred into a plasmid with tetracycline-inducible gene 
expression (pcDNA4/TO; Invitrogen). In my experimental approach, 
TREX293 tet-on cells (expressing the tetracycline (Tet) repressor under the 
control of the human cytomegalovirus immediate-early promoter) were 
transfected with tetracycline inducible vector pcDNA4/TO containing Skp1a-
V5 and Skp1b-V5. One day after transfection, tetracycline was added in the 
presence of the protein synthesis inhibitor cycloheximide. Under these 
conditions, Skp1a-V5 and Skp1b-V5 mRNA will be transcribed but no protein 
will be synthesized. After 3 hours, cycloheximide was washed out. The cells 
were then lysed at different times to measure the accumulation of newly 
synthesized Skp1a-V5 and Skp1b-V5 protein. As observed in lanes 1 and 7, 
we noted that there is some basal background expression of Skp1a-V5 and 
Skp1b-V5 protein in the absence of tetracycline. However, importantly, there 
was no increase (but actually a small decrease) in Skp1a-V5 and Skp1b-V5 
protein in the presence of tetracycline plus cycloheximide (lanes 2 and 8 in 
Figure 5.13, respectively), indicating that the protein synthesis inhibitor 
effectively blocked translation. Upon cycloheximide washout, we noted a 
similar steady increase in the protein expression of Skp1a-V5 and Skp1b-V5 
over time. This suggests that the different expression levels of Skp1a-V5 and 





Figure 5.13. Skp1a-V5 and Skp1b-V5 are translated with similar 
efficiency. Tetracycline inducible Skp1a-V5 (2 µg) and Skp1b-V5 (0.1 µg) 
plasmid was transfected into TREX293 cells. Cells were treated for 3 hours 
with 40 µM cycloheximide (CHX) and 1 µg/ml tetracycline (tet) prior to 
cycloheximide washout (at time zero) and incubation with tetracycline for the 
indicated times. Equal protein amounts were loaded as determined by 
Bradford assay and analysed by Western blot analysis. 
 
In summary, our results indicate that the Skp1b isoform is expressed at 
significantly higher levels compared to Skp1a. This is primarily due to 
preferential splicing of Skp1b. In addition, other post-translational 
mechanisms may contribute to the low expression of Skp1a. However, the 




5.2.5 Intracellular protein localization of Skp1a and Skp1b 
We next wanted to determine whether there are functional differences between 
the two Skp1 isoforms. As the activity of a protein is dependent on its 
subcellular localization and molecular interaction with its binding partners, we 
first examined whether there are differences in the intracellular protein 
localization of Skp1a and Skp1b. As the presence of an epitope tag can 
sometimes affect the protein localization, we used versions of Skp1a and 
Skp1b protein that carry either an N-terminal or a C-terminal V5 tag. 
Therefore, N-terminally and C-terminally V5-tagged Skp1a and Skp1b 
expression plasmids were transfected into cells and immunofluorescence was 
performed to determine the protein localization. To ensure accurate 
quantification, blind scoring of the cells was carried out on two biological 
replicates. We scored the cells based on the localization pattern between the 
nucleus and cytoplasm. Based on the results shown in Figure 5.14, the Skp1a 
protein has a more equal distribution between the nucleus and cytoplasm, 
whereas Skp1b is found to have a higher distribution in the nucleus. 
Comparing between the N-terminally and C-terminally tagged Skp1a and 
Skp1b proteins, we observed similar results regardless of the V5-tag location 
(Figure 5.14A and 5.14B). Thus, both N-terminally and C-terminally V5-
tagged Skp1a protein localized less to the nucleus than Skp1b. We also noted 
that similar to Skp1b, Skp1a does not form aggregates based on the 














Figure 5.14. Cellular protein distribution of (A) C-terminal and (B) N-
terminal V5 tagged Skp1 proteins. HEK293T cells were transfected with 
either 2 µg Skp1a-V5, 2 µg V5-Skp1a, 0.1 µg Skp1b-V5 or 0.1 µg V5-Skp1b. 
Immunofluorescence was carried out as described in Materials and Methods. 
Results were quantified by counting the indicated cell number of two 






Figure 5.15. Representative pictures of N-terminal and C-terminal V5 
tagged Skp1 proteins. HEK293T cells were transfected with either 2 µg 
Skp1a-V5, 2 µg V5-Skp1a, 0.1 µg Skp1b-V5 or 0.1 µg V5-Skp1b. 









5.2.6 Skp1a and Skp1b binding to CRL components  
We next examined whether the different C-terminal amino acid sequences 
affect the affinity of Skp1a and Skp1b to other SCF subunits. To determine the 
binding of Skp1a and Skp1b to proteins in the SCF complex, 
immunoprecipitation experiments were carried out. 
 
We first determined the binding of V5-Skp1a and V5-Skp1b to Cullin1. Cells 
were transfected with Cul1-Flag and co-transfected with either V5-Skp1a or 
V5-Skp1b. Subsequently, V5-immunoprecipiation was carried out. We 
observed no difference in the binding of V5-Skp1a or V5-Skp1b to Cul1-Flag.  
 
 
Figure 5.16. Binding to V5-Skp1a and V5-Skp1b to Cullin1 is similar. 
HEK293T cells were transfected with 1.5 µg Cul1-Flag, 4 µg V5-Skp1a or 0.2 
µg V5-Skp1b, as indicated. Equal protein amounts of cell lysates were 




Similarly, we performed V5-IP using lysates from cells expressing HA-Skp2 
and either V5-Skp1a or V5-Skp1b. We observed that there is lesser binding of 
Skp1a to Skp2 compared to Skp1b even though Skp1a and Skp1b were 
expressed at similar levels in the lysate (Figure 5.17 lanes 7 and 8).  
 
 
Figure 5.17. Binding affinity of N-terminally V5-tagged Skp1a and Skp1b 
to Skp2. HEK293T cells were transfected with 1.5 µg HA-Skp2, 4 µg V5-
Skp1a or 0.2 µg V5-Skp1b as indicated. Equal protein amount was loaded and 
subjected to immunoprecipitation as described in Materials and Methods. The 
asterisk denotes immunoglobulin heavy chain. 
 
 
In the previous experiment (Figure 5.17), we used N-terminally tagged 
versions of Skp1a and Skp1b. To confirm that the N-terminal V5 tag does not 
interfere with the binding of Skp1 to Skp2, we repeated the 
immunoprecipitation experiment using C-terminal V5 tagged Skp1 constructs. 
As observed in Figure 5.14, binding between Skp1b-V5 and HA-Skp2 could 
be readily detected. In contrast, in the Skp1a-V5 immunoprecipitate (Figure 
5.18, lane 2), only a faint band for HA-Skp2 could be seen upon closer 
inspection of the film, suggesting that Skp1a-V5 binds to HA-Skp2 weakly. 
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This result is similar to what we have previously observed with the N-
terminally V5-tagged Skp1 constructs (Figure 5.17). Taken together, the 
results suggest that Skp1a and Skp1b both bind to Cullin 1 and Skp2. However, 
the binding of Skp1a to Skp2 is weaker compared to Skp1b.  
 
Figure 5.18. Binding of C-terminally V5-tagged Skp1a and Skp1b to HA-
Skp2. HEK293T cells were transfected with 1.5 µg HA-Skp2, 4 µg Skp1a-V5 
or 0.2 µg Skp1b-V5, as indicated. Equal protein amount were subjected to 
immunoprecipitation as described in Materials and Methods. The asterisks on 
the HA blots denote immunoglobulin heavy chain, and the asterisk on the V5 
blot denotes immunoglobulin light chain. 
 
 
5.2.7 SGT1 regulation of Skp1a and Skp1b 
Skp1 is also known to bind to the SGT1 protein, which is not part of the CRL 
complex. SGT1 has been implicated to play a role in kinetochore assembly 
(Davies & Kaplan 2010). We therefore sought to determine if Skp1a and 
Skp1b interact with SGT1 with different binding affinities. We first performed 
immunoprecipitation of Flag-SGT1 to confirm binding of endogenous Skp1 to 
SGT1. Although Flag-SGT1 was greatly enriched in the Flag-IP compared to 
107 
 
the cell lysate, we did not detect binding of endogenous Skp1 and Cullin1 to 
SGT1 (Figure 5.19). We then cotransfected Skp1a-V5 and Skp1b-V5 with 
FLAG-SGT1 and performed FLAG-immunoprecipitation. We were only able 
to detect faint binding of Skp1b-V5 to FLAG-SGT1, even though Skp1a-V5 
and Skp1b-V5 were expressed at similar levels (Figure 5.20). In conclusion, 
our results suggest that Skp1b has a higher binding affinity for SGT1 
compared to Skp1a, for which no binding could be detected. 
 
Figure 5.19. Endogenous Cullin1 and Skp1 does not bind to Flag-SGT1. 
HEK293T cells were transfected with Flag-SGT1. Equal protein amounts were 
subjected to immunoprecipitation using Flag-agarose beads as described in 





Figure 5.20. SGT1 binding to transfected Skp1a and Skp1b. HEK293T 
cells were transfected with Flag-SGT1, 4 µg Skp1a-V5 or 0.2 µg Skp1b-V5, 
as indicated. Equal protein amounts were subjected to immunoprecipitation as 
described in Materials and Methods. In the upper panel in lane 5 a very faint 





In contrast to various organisms (Dictyostelium and Arabidopsis thaliana) that 
have multiple Skp1 isoforms arising from multiple genes, only one Skp1 gene 
is found in humans. However, there are two protein variants (Skp1a and 
Skp1b) with different C-terminal amino acid sequence. This is due to intron 
retention of the mature Skp1 mRNA transcript. Intron retention is one of the 
alternative splicing mechanisms, where an intron is not spliced out and is 
incorporated into the mature mRNA transcript (Keren, Lev-Maor & Ast 2010). 
Our study is the first to characterize the Skp1a isoform in detail, by examining 





Our results indicate that at the endogenous level, Skp1a is only weakly 
expressed compared to Skp1b. We found that there is lower Skp1a mRNA 
compared to Skp1b in three different cell lines. Furthermore, this difference in 
mRNA expression is not due to differences in mRNA decay, but most likely a 
consequence of preferential splicing of Skp1b compared to Skp1a. 
 
In addition, we observed that a post-translational mechanism also contributes 
to the low Skp1a protein expression levels. Thus, we found that transfecting 
equal amounts of Skp1a and Skp1b leads to dramatically lower Skp1a protein 
expression, despite similar plasmid driven mRNA transcription. Our results 
indicate that the low Skp1a protein expression is not due to differences in the 
efficiency of mRNA translation or in the rate of proteasome- and autophagy-
dependent protein degradation. 
 
Low Skp1a protein expression levels may also be due to low efficiency of 
protein folding, where misfolded proteins are often insoluble and might be 
subjected to protease mediated cleavage. Therefore, the protein would not be 
detected in the Western blot analysis. Bioinformatics analysis was carried out 
to determine the disorder score of the Skp1 proteins. The disorder score is 
based on calculating the hydrophobicity of the amino acids, where a higher 
score reflects a more hydrophobic region. As hydrophobic interactions control 
protein folding, the disorder score is an indication of the propensity of the 
protein to have a defined secondary structure. Using two independent 
bioinformatics analyses, we found that the C-terminus of Skp1a is less 
disordered compared to Skp1b. This would predict that the Skp1a C-terminus 
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is more folded. However, our experimental data suggest otherwise, where the 
trypsin digestion assay indicated that Skp1a is more prone to trypsin-mediated 
cleavage, presumably due to a more unfolded state of the protein. It is thus 
possible that the full-length Skp1a is more likely to be cleaved by intracellular 
proteases as it is more unfolded. This in turn may contribute to the observed 
low protein expression of Skp1a. Another possible explanation for the low 
Skp1a protein abundance may be the regulation of its protein expression under 
specific cellular conditions. 
 
In our study, we also characterized any functional differences between the two 
Skp1 splice variants. Thus, we investigated the intracellular protein 
localization of Skp1a and Skp1b as well as the binding to interacting partners. 
A difference in protein localization might give clues about the function of 
Skp1a. It is known that proteins smaller than 50kDa can passively diffuse 
through the nuclear pore complexes (Shimozono, Tsutsui & Miyawaki 2009). 
Given that both Skp1a and Skp1b protein are about 19kDa in size, we would 
expect equal distribution of the proteins in both nucleus and cytoplasm. 
However, we observed a greater distribution of Skp1b to the nucleus. This 
might be a consequence of regulatory signals that govern the protein 
localization or of differential binding of Skp1a and Skp1b to interacting 
partners. The immunoprecipitation results demonstrate that both Skp1a and 
Skp1b bind to Cullin1 with similar affinity. In contrast, Skp1a binds to Skp2 
much more weakly than Skp1b. As Skp1 acts as the adaptor protein between 
Cullin1 and F-box proteins such as Skp2, it is possible that Skp1a can act as a 
dominant negative regulator by binding to the Cullin1 scaffold protein (Figure 
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5B). This would sequester the functional subunits needed and prevent the 
assembly of the active SCF complex, leading to less effective substrate 
ubiquitination. In this regard, it would be interesting to determine if Skp1a 
mRNA and protein expression is regulated in response to specific 
physiological signals. Another possibility is that Skp1a and Skp1b have 
differential affinities for specific F-box proteins. Thus, upregulation of Skp1a 
under certain conditions could potentially regulate the degradation efficiency 
of SCF, and this would be important to examine in future studies. 
 
 
Figure 5C. Proposed model for Skp1a and Skp1b 
(A) Skp1a has lower affinity for Skp2, one of the 69 F-box proteins. Upon 
binding to Cullin1, Skp1a may exert a dominant negative effect by 
sequestering Cullin1 subunits required for degradation of substrates. (B) 
Skp1b binds to Skp2 F-box protein with higher affinity. The assembly of the 
Skp1-F-box substrate receptor module on Cullin1 creates a functional Cullin1 




Another protein, SGT1, has been reported to bind to Skp1. SGT1 was first 
discovered to have an essential role in the yeast kinetochore assembly pathway 
that is dependent on its homodimerization (Bansal et al. 2009; Kitagawa et al. 
1999). In mammalian cells, SGT1 has been shown to bind to Skp1 to play a 
role in kinetochore assembly (Davies & Kaplan 2010). However, in our 
studies, we were only able to detect a weak interaction between Skp1b and 
SGT1. Of note, no interaction between Skp1a and SGT1 could be detected in 
our coimmunoprecipitation experiments. These results suggest that there are 
functional differences between the two Skp1 splice variants with regards to 






6.0 Conclusion and future work 
Cullin E3 ligases form an important family of E3 ubiquitin ligases that exert 
control over cellular pathways by regulating the protein half-life. In chapter 3, 
the function of Cullin5 in relation to IRS1 degradation was studied. SOCS 
proteins have been reported to regulate IRS1 activity & protein stability and 
these proteins are known to function as substrate recognition receptors in 
Cullin5-based E3 ubiquitin ligases. We therefore hypothesized that Cullin5 is 
involved in controlling IRS1 protein stability. However, we found that 
Cullin5-based E3 ligases do not mediate the basal as well as the signal-
induced degradation of IRS1. Hence, other E3 ubiquitin ligases are likely to be 
involved in catalyzing IRS1 protein ubiquitination. Given the 
pathophysiological significance of IRS1 in insulin resistance and type 2 
diabetes, it would be important to characterize these ubiquitination 
mechanisms in detail. 
 
In chapter 4, we studied the regulation of the substrate receptor module, 
consisting of the adapter protein Skp1 and the F-box protein substrate 
recognition subunit. To study the regulation of the substrate receptor module, 
we chose the F-box protein Skp2 as a model. Using this model, we determined 
the ratio of Skp1 and Skp2 protein in the cell. We also studied whether the 
Skp2 protein can exist in a Skp1-independent form and whether Skp1 plays a 
role in regulating Skp2 protein steady-state levels. Our main conclusions are 
that Skp1 exists in moderate excess over Skp2 in cells. However, the majority 
of Skp2 exists in a non-Skp1 bound form in cells. Furthermore, Skp2 protein 
stability is not significantly affected by binding to Skp1. Based on our results 
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we propose that a large portion of Skp2 and likely other F-box proteins exists 
in a free, non-Skp1 bound form. F-box proteins are likely to dynamically 
associate with Skp1 and compete for interaction with Skp1. These results 
suggest that targeting the Skp1-F-box interaction may be a promising strategy 
for the inhibition of Cullin E3 ligases. 
 
In chapter 5, we studied the largely uncharacterized Skp1 splice variant Skp1a. 
We found that compared to the well-studied Skp1b variant, Skp1a expression 
is low in all examined cell lines. The low Skp1a expression is due to 
preferential splicing of Skp1b as well as a post-translational regulatory 
mechanism. The exact nature of this post-translational mechanism is currently 
not clear, but it is likely to involve a more unfolded state of Skp1a, leading 
potentially to aggregation or proteolytic cleavage. Functionally, we found 
differences between Skp1a and Skp1b in terms of their nucleo-cytoplasmic 
distribution and their interaction with the F-box protein Skp2 and the 
kinetochore assembly factor SGT1. However, the physiological significance of 
these different functional characteristics is currently not clear and requires 
further study. Specific questions of interest arising from our research include a 
potential role of Skp1a acting as a dominant negative protein in the assembly 
of the SCF complex. Alternatively, Skp1a may have differential affinity for 
different F-box proteins. It would also be interesting to determine if there are 
binding factors that can promote the binding of Skp1a to the SCF complex and 
whether this binding is regulated under any stimuli. Currently, it is also not 
known if there are stimuli that can selectively upregulate the protein 
expression of Skp1a. Taken together, chapters 4 and 5 suggest a dynamic 
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association of Skp1a/Skp1b and F-box proteins in the cell, contributing to the 
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